Hubbry Logo
logo
MicroRNA
Community hub

MicroRNA

logo
0 subscribers
Read side by side
from Wikipedia

Pre-miRNA instead of Pri-miRNA in the first point of mechanism. Diagram of microRNA (miRNA) action with mRNA
Examples of miRNA hairpins (stem-loops), with the mature miRNAs shown in red

Micro ribonucleic acid (microRNA, miRNA, μRNA) are small, single-stranded, non-coding RNA molecules containing 21–23 nucleotides.[1] Found in plants, animals, and even some viruses, miRNAs are involved in RNA silencing and post-transcriptional regulation of gene expression.[2][3] miRNAs base-pair to complementary sequences in messenger RNA (mRNA) molecules,[4] then silence said mRNA molecules by one or more of the following processes:[1][5]

  • Cleaving the mRNA strand into two pieces.
  • Destabilizing the mRNA by shortening its poly(A) tail.
  • Reducing translation of the mRNA into proteins.

In cells of humans and other animals, miRNAs primarily act by destabilizing the mRNA.[6][7]

miRNAs resemble the small interfering RNAs (siRNAs) of the RNA interference (RNAi) pathway, except miRNAs derive from regions of RNA transcripts that fold back on themselves to form short stem-loops (hairpins), whereas siRNAs derive from longer regions of double-stranded RNA.[2] The human genome may encode over 1900 miRNAs,[8][9] However, only about 500 human miRNAs represent bona fide miRNAs in the manually curated miRNA gene database MirGeneDB.[10]

miRNAs are abundant in many mammalian cell types.[11][12] They appear to target about 60% of the genes of humans and other mammals.[13][14] Many miRNAs are evolutionarily conserved, which implies that they have important biological functions.[15][1] For example, 90 families of miRNAs have been conserved since at least the common ancestor of mammals and fish, and most of these conserved miRNAs have important functions, as shown by studies in which genes for one or more members of a family have been knocked out in mice.[1]

In 2024, American scientists Victor Ambros and Gary Ruvkun were awarded the Nobel Prize in Physiology or Medicine for their work on the discovery of miRNA and its role in post-transcriptional gene regulation.[16][17][18]

History

[edit]

The first miRNA was discovered in the early 1990s.[19] However, they were not recognized as a distinct class of biological regulators until the early 2000s.[20][21][22][23][24] Research revealed different sets of miRNAs expressed in different cell types and tissues[12][25] and multiple roles for miRNAs in plant and animal development and in many other biological processes.[26][27][28][29][30][31][32] Aberrant miRNA expression are implicated in disease states. MiRNA-based therapies are under investigation.[33][34][35][36]

The first miRNA was discovered in 1993 by a group led by Victor Ambros and including Lee and Feinbaum. However, additional insight into its mode of action required simultaneously published work by Gary Ruvkun's team, including Wightman and Ha.[19][37] These groups published back-to-back papers on the lin-4 gene, which was known to control the timing of C. elegans larval development by repressing the lin-14 gene. When Lee et al. isolated the lin-4 miRNA, they found that instead of producing an mRNA encoding a protein, it produced short non-coding RNAs, one of which was a ~22-nucleotide RNA that contained sequences partially complementary to multiple sequences in the 3' UTR of the lin-14 mRNA.[19] This complementarity was proposed to inhibit the translation of the lin-14 mRNA into the LIN-14 protein. At the time, the lin-4 small RNA was thought to be a nematode idiosyncrasy.

In 2000, a second small RNA was characterized: let-7 RNA, which represses lin-41 to promote a later developmental transition in C. elegans.[20] The let-7 RNA was found to be conserved in many species, leading to the suggestion that let-7 RNA and additional "small temporal RNAs" might regulate the timing of development in diverse animals, including humans.[21]

A year later, the lin-4 and let-7 RNAs were found to be part of a large class of small RNAs present in C. elegans, Drosophila and human cells.[22][23][24] The many RNAs of this class resembled the lin-4 and let-7 RNAs, except their expression patterns were usually inconsistent with a role in regulating the timing of development. This suggested that most might function in other types of regulatory pathways. At this point, researchers started using the term "microRNA" to refer to this class of small regulatory RNAs.[22][23][24]

The first human disease associated with deregulation of miRNAs was chronic lymphocytic leukemia. In this disorder, the miRNAs have a dual role working as both tumor suppressors and oncogenes.[38]

Nomenclature

[edit]

Under a standard nomenclature system, names are assigned to experimentally confirmed miRNAs before publication.[39][40] The prefix "miR" is followed by a dash and a number, the latter often indicating order of naming. For example, miR-124 was named and likely discovered prior to miR-456. A capitalized "miR-" refers to the mature form of the miRNA, while the uncapitalized "mir-" refers to the pre-miRNA and the pri-miRNA.[41] The genes encoding miRNAs are also named using the same three-letter prefix according to the conventions of the organism gene nomenclature. For examples, the official miRNAs gene names in some organisms are "mir-1 in C. elegans and Drosophila, Mir1 in Rattus norvegicus and MIR25 in human. [citation needed]

miRNAs with nearly identical sequences except for one or two nucleotides are annotated with an additional lower case letter. For example, miR-124a is closely related to miR-124b. For example:

hsa-miR-181a: aacauucaACgcugucggugAgu
hsa-miR-181b: aacauucaUUgcugucggugGgu

Pre-miRNAs, pri-miRNAs and genes that lead to 100% identical mature miRNAs but that are located at different places in the genome are indicated with an additional dash-number suffix. For example, the pre-miRNAs hsa-mir-194-1 and hsa-mir-194-2 lead to an identical mature miRNA (hsa-miR-194) but are from genes located in different genome regions.[citation needed]

Species of origin is designated with a three-letter prefix, e.g., hsa-miR-124 is a human (Homo sapiens) miRNA and oar-miR-124 is a sheep (Ovis aries) miRNA. Other common prefixes include "v" for viral (miRNA encoded by a viral genome) and "d" for Drosophila miRNA (a fruit fly commonly studied in genetic research).[citation needed]

When two mature microRNAs originate from opposite arms of the same pre-miRNA and are found in roughly similar amounts, they are denoted with a -3p or -5p suffix. (In the past, this distinction was also made with "s" (sense) and "as" (antisense)). However, the mature microRNA found from one arm of the hairpin is usually much more abundant than that found from the other arm,[2] in which case, an asterisk following the name indicates the mature species found at low levels from the opposite arm of a hairpin. For example, miR-124 and miR-124* share a pre-miRNA hairpin, but much more miR-124 is found in the cell.

Targets

[edit]

Plant miRNAs usually have near-perfect pairing with their mRNA targets, which induces gene repression through cleavage of the target transcripts.[26][42] In contrast, animal miRNAs are able to recognize their target mRNAs by using as few as 6–8 nucleotides (the seed region) at the 5' end of the miRNA,[13][43][44] which is not enough pairing to induce cleavage of the target mRNAs.[4] Combinatorial regulation is a feature of miRNA regulation in animals.[4][45] A given miRNA may have hundreds of different mRNA targets, and a given target might be regulated by multiple miRNAs.[14][46]

Estimates of the average number of unique messenger RNAs that are targets for repression by a typical miRNA vary, depending on the estimation method,[47] but multiple approaches show that mammalian miRNAs can have many unique targets. For example, an analysis of the miRNAs highly conserved in vertebrates shows that each has, on average, roughly 400 conserved targets.[14] Likewise, experiments show that a single miRNA species can reduce the stability of hundreds of unique messenger RNAs.[48] Other experiments show that a single miRNA species may repress the production of hundreds of proteins, but that this repression often is relatively mild (much less than 2-fold).[49][50]

Biogenesis

[edit]

As many as 40% of miRNA genes may lie in the introns or even exons of other genes.[51] These are usually, though not exclusively, found in a sense orientation,[52][53] and thus usually are regulated together with their host genes.[51][54][55]

The DNA template is not the final word on mature miRNA production: 6% of human miRNAs show RNA editing (IsomiRs), the site-specific modification of RNA sequences to yield products different from those encoded by their DNA. This increases the diversity and scope of miRNA action beyond that implicated from the genome alone.[citation needed]

Transcription

[edit]

miRNA genes are usually transcribed by RNA polymerase II (Pol II).[56][57] The polymerase often binds to a promoter found near the DNA sequence, encoding what will become the hairpin loop of the pre-miRNA. The resulting transcript is capped with a specially modified nucleotide at the 5' end, polyadenylated with multiple adenosines (a poly(A) tail),[56][52] and spliced. Animal miRNAs are initially transcribed as part of one arm of an ~80 nucleotide RNA hairpin that in turn forms part of a several hundred nucleotide-long miRNA precursor termed a pri-miRNA.[56][52] When a hairpin precursor is found in the 3' UTR, a transcript may serve as a pri-miRNA and a mRNA.[52] RNA polymerase III (Pol III) transcribes some miRNAs, especially those with upstream Alu sequences, transfer RNAs (tRNAs), and mammalian wide interspersed repeat (MWIR) promoter units.[58]

Nuclear processing

[edit]
A crystal structure of the human Drosha protein in complex with the C-terminal helices of two DGCR8 molecules (green). Drosha consists of two ribonuclease III domains (blue and orange); a double-stranded RNA binding domain (yellow); and a connector/platform domain (gray) containing two bound zinc ion (spheres). From PDB: 5B16​.

A single pri-miRNA may contain from one to six miRNA precursors. These hairpin loop structures are composed of about 70 nucleotides each. Each hairpin is flanked by sequences necessary for efficient processing.[citation needed]

The double-stranded RNA (dsRNA) structure of the hairpins in a pri-miRNA is recognized by a nuclear protein known as DiGeorge Syndrome Critical Region 8 (DGCR8 or "Pasha" in invertebrates), named for its association with DiGeorge Syndrome. DGCR8 associates with the enzyme Drosha, a protein that cuts RNA, to form the Microprocessor complex.[59][60] In this complex, DGCR8 orients the catalytic RNase III domain of Drosha to liberate hairpins from pri-miRNAs by cleaving RNA about eleven nucleotides from the hairpin base (one helical dsRNA turn into the stem).[61][62] The product resulting has a two-nucleotide overhang at its 3' end; it has 3' hydroxyl and 5' phosphate groups. It is often termed as a pre-miRNA (precursor-miRNA). Sequence motifs downstream of the pre-miRNA that are important for efficient processing have been identified.[63][64][65]

Pre-miRNAs that are spliced directly out of introns, bypassing the Microprocessor complex, are known as "mirtrons."[66] Mirtrons have been found in Drosophila, C. elegans, and mammals.[66][67]

As many as 16% of pre-miRNAs may be altered through nuclear RNA editing.[68][69][70] Most commonly, enzymes known as adenosine deaminases acting on RNA (ADARs) catalyze adenosine to inosine (A to I) transitions. RNA editing can halt nuclear processing (for example, of pri-miR-142, leading to degradation by the ribonuclease Tudor-SN) and alter downstream processes including cytoplasmic miRNA processing and target specificity (e.g., by changing the seed region of miR-376 in the central nervous system).[68]

Nuclear export

[edit]
The human exportin-5 protein (red) in complex with Ran-GTP (yellow) and a pre-microRNA (green), showing two-nucleotide overhang recognition element (orange). From PDB: 3A6P​.

Pre-miRNA hairpins are exported from the nucleus in a process involving the nucleocytoplasmic shuttler Exportin-5. This protein, a member of the karyopherin family, recognizes a two-nucleotide overhang left by the RNase III enzyme Drosha at the 3' end of the pre-miRNA hairpin. Exportin-5-mediated transport to the cytoplasm is energy-dependent, using guanosine triphosphate (GTP) bound to the Ran protein.[71]

Cytoplasmic processing

[edit]

In the cytoplasm, the pre-miRNA hairpin is cleaved by the RNase III enzyme Dicer.[72] This endoribonuclease interacts with 5' and 3' ends of the hairpin[73] and cuts away the loop joining the 3' and 5' arms, yielding an imperfect miRNA:miRNA* duplex about 22 nucleotides in length.[72] Overall hairpin length and loop size influence the efficiency of Dicer processing. The imperfect nature of the miRNA:miRNA* pairing also affects cleavage.[72][74] Some of the G-rich pre-miRNAs can potentially adopt the G-quadruplex structure as an alternative to the canonical hairpin structure. For example, human pre-miRNA 92b adopts a G-quadruplex structure which is resistant to the Dicer mediated cleavage in the cytoplasm.[75] Although either strand of the duplex may potentially act as a functional miRNA, only one strand is usually incorporated into the RNA-induced silencing complex (RISC) where the miRNA and its mRNA target interact.

While the majority of miRNAs are located within the cell, some miRNAs, commonly known as circulating miRNAs or extracellular miRNAs, have also been found in extracellular environment, including various biological fluids and cell culture media.[76][77]

Biogenesis in plants

[edit]

miRNA biogenesis in plants differs from animal biogenesis mainly in the steps of nuclear processing and export. Instead of being cleaved by two different enzymes, once inside and once outside the nucleus, both cleavages of the plant miRNA are performed by a Dicer homolog, called Dicer-like1 (DL1). DL1 is expressed only in the nucleus of plant cells, which indicates that both reactions take place inside the nucleus. Before plant miRNA:miRNA* duplexes are transported out of the nucleus, its 3' overhangs are methylated by a RNA methyltransferaseprotein called Hua-Enhancer1 (HEN1). The duplex is then transported out of the nucleus to the cytoplasm by a protein called Hasty (HST), an Exportin 5 homolog, where they disassemble and the mature miRNA is incorporated into the RISC.[78]

RNA-induced silencing complex

[edit]

The mature miRNA is part of an active RNA-induced silencing complex (RISC) containing Dicer and many associated proteins.[79] RISC is also known as a microRNA ribonucleoprotein complex (miRNP);[80] A RISC with incorporated miRNA is sometimes referred to as a "miRISC."

Dicer processing of the pre-miRNA is thought to be coupled with unwinding of the duplex. Generally, only one strand is incorporated into the miRISC, selected on the basis of its thermodynamic instability and weaker base-pairing on the 5' end relative to the other strand.[81][82][83] The position of the hairpin may also influence strand choice.[84] The other strand, called the passenger strand due to its lower levels in the steady state, is denoted with an asterisk (*) and is normally degraded. In some cases, both strands of the duplex are viable and become functional miRNA that target different mRNA populations.[85]

AGO2 (grey) in complex with a microRNA (light blue) and its target mRNA (dark blue)

Members of the Argonaute (Ago) protein family are central to RISC function. Argonautes are needed for miRNA-induced silencing and contain two conserved RNA binding domains: a PAZ domain that can bind the single stranded 3' end of the mature miRNA and a PIWI domain that structurally resembles ribonuclease-H and functions to interact with the 5' end of the guide strand. They bind the mature miRNA and orient it for interaction with a target mRNA. Some argonautes, for example human Ago2, cleave target transcripts directly; argonautes may also recruit additional proteins to achieve translational repression.[86] The human genome encodes eight argonaute proteins divided by sequence similarities into two families: AGO (with four members present in all mammalian cells and called E1F2C/hAgo in humans), and PIWI (found in the germline and hematopoietic stem cells).[80][86]

Additional RISC components include TRBP [human immunodeficiency virus (HIV) transactivating response RNA (TAR) binding protein],[87] PACT (protein activator of the interferon-induced protein kinase), the SMN complex, fragile X mental retardation protein (FMRP), Tudor staphylococcal nuclease-domain-containing protein (Tudor-SN), the putative DNA helicase MOV10, and the RNA recognition motif containing protein TNRC6B.[71][88][89]

Mode of silencing and regulatory loops

[edit]

Gene silencing may occur either via mRNA degradation or preventing mRNA from being translated. For example, miR16 contains a sequence complementary to the AU-rich element[90] found in the 3'UTR of many unstable mRNAs, such as TNF alpha or GM-CSF.[91] It has been demonstrated that given complete complementarity between the miRNA and target mRNA sequence, Ago2 can cleave the mRNA and lead to direct mRNA degradation. In the absence of complementarity, silencing is achieved by preventing translation.[48] The relation of miRNA and its target mRNA can be based on the simple negative regulation of a target mRNA, but it seems that a common scenario is the use of a "coherent feed-forward loop", "mutual negative feedback loop" (also termed double negative loop) and "positive feedback/feed-forward loop". Some miRNAs work as buffers of random gene expression changes arising due to stochastic events in transcription, translation and protein stability. Such regulation is typically achieved by the virtue of negative feedback loops or incoherent feed-forward loop uncoupling protein output from mRNA transcription.[citation needed]

Turnover

[edit]

Turnover of mature miRNA is needed for rapid changes in miRNA expression profiles. During miRNA maturation in the cytoplasm, uptake by the Argonaute protein is thought to stabilize the guide strand, while the opposite (* or "passenger") strand is preferentially destroyed. In what has been called a "Use it or lose it" strategy, Argonaute may preferentially retain miRNAs with many targets over miRNAs with few or no targets, leading to degradation of the non-targeting molecules.[92]

Decay of mature miRNAs in Caenorhabditis elegans is mediated by the 5'-to-3' exoribonuclease XRN2, also known as Rat1p.[93] In plants, SDN (small RNA degrading nuclease) family members degrade miRNAs in the opposite (3'-to-5') direction. Similar enzymes are encoded in animal genomes, but their roles have not been described.[92]

Several miRNA modifications affect miRNA stability. As indicated by work in the model organism Arabidopsis thaliana (thale cress), mature plant miRNAs appear to be stabilized by the addition of methyl moieties at the 3' end. The 2'-O-conjugated methyl groups block the addition of uracil (U) residues by uridyltransferase enzymes, a modification that may be associated with miRNA degradation. However, uridylation may also protect some miRNAs; the consequences of this modification are incompletely understood. Uridylation of some animal miRNAs has been reported. Both plant and animal miRNAs may be altered by addition of adenine (A) residues to the 3' end of the miRNA. An extra A added to the end of mammalian miR-122, a liver-enriched miRNA important in hepatitis C, stabilizes the molecule and plant miRNAs ending with an adenine residue have slower decay rates.[92]

Cellular functions

[edit]
Interaction of microRNA with protein translation process. Several translation repression mechanisms are shown: M1) on the initiation process, preventing assembling of the initiation complex or recruiting the 40S ribosomal subunit; M2) on the ribosome assembly; M3) on the translation process; M7, M8) on the degradation of mRNA.[94] 40S and 60S are light and heavy components of the ribosome, 80S is the assembled ribosome bound to mRNA, eIF4F is a translation initiation factor, PABC1 is the Poly-A binding protein, and "cap" is the mRNA cap structure needed for mRNA circularization (which can be the normal m7G-cap or modified A-cap). The initiation of mRNA can proceed in a cap-independent manner, through recruiting 40S to IRES (Internal Ribosome Entry Site) located in 5'UTR region. The actual work of RNA silencing is performed by RISC in which the main catalytic subunit is one of the Argonaute proteins (AGO), and miRNA serves as a template for recognizing specific mRNA sequences.

The function of miRNAs appears to be in gene regulation. For that purpose, a miRNA is complementary to a part of one or more messenger RNAs (mRNAs). Animal miRNAs are usually complementary to a site in the 3' UTR whereas plant miRNAs are usually complementary to coding regions of mRNAs.[95] Perfect or near perfect base pairing with the target RNA promotes cleavage of the RNA.[96] This is the primary mode of plant miRNAs.[97] In animals the match-ups are imperfect.

For partially complementary microRNAs to recognise their targets, nucleotides 2–7 of the miRNA (its 'seed region'[13][43]) must be perfectly complementary.[98] Animal miRNAs inhibit protein translation of the target mRNA[99] (this is present but less common in plants).[97] Partially complementary microRNAs can also speed up deadenylation, causing mRNAs to be degraded sooner.[100] While degradation of miRNA-targeted mRNA is well documented, whether or not translational repression is accomplished through mRNA degradation, translational inhibition, or a combination of the two is hotly debated. Recent work on miR-430 in zebrafish, as well as on bantam-miRNA and miR-9 in Drosophila cultured cells, shows that translational repression is caused by the disruption of translation initiation, independent of mRNA deadenylation.[101][102]

miRNAs occasionally also cause histone modification and DNA methylation of promoter sites, which affects the expression of target genes.[103][104]

Nine mechanisms of miRNA action are described and assembled in a unified mathematical model:[94]

  • Cap-40S initiation inhibition;
  • 60S Ribosomal unit joining inhibition;
  • Elongation inhibition;
  • Ribosome drop-off (premature termination);
  • Co-translational nascent protein degradation;
  • Sequestration in P-bodies;
  • mRNA decay (destabilisation);
  • mRNA cleavage;
  • Transcriptional inhibition through microRNA-mediated chromatin reorganization followed by gene silencing.

It is often impossible to discern these mechanisms using experimental data about stationary reaction rates. Nevertheless, they are differentiated in dynamics and have different kinetic signatures.[94]

Unlike plant microRNAs, the animal microRNAs target diverse genes.[43] However, genes involved in functions common to all cells, such as gene expression, have relatively fewer microRNA target sites and seem to be under selection to avoid targeting by microRNAs.[105] There is a strong correlation between ITPR gene regulations and mir-92 and mir-19.[106]

dsRNA can also activate gene expression, a mechanism that has been termed "small RNA-induced gene activation" or RNAa. dsRNAs targeting gene promoters can induce potent transcriptional activation of associated genes. This was demonstrated in human cells using synthetic dsRNAs termed small activating RNAs (saRNAs),[107] but has also been demonstrated for endogenous microRNA.[108]

Interactions between microRNAs and complementary sequences on genes and even pseudogenes that share sequence homology are thought to be a back channel of communication regulating expression levels between paralogous genes (genes having a similar structure indicating divergence from a common ancestral gene). Given the name "competing endogenous RNAs" (ceRNAs), these microRNAs bind to "microRNA response elements" on genes and pseudogenes and may provide another explanation for the persistence of non-coding DNA.[109]

miRNAs are also found as extracellular circulating miRNAs.[110] Circulating miRNAs are released into body fluids including blood and cerebrospinal fluid and have the potential to be available as biomarkers in a number of diseases.[110][111] Some researches show that mRNA cargo of exosomes may have a role in implantation, they can savage an adhesion between trophoblast and endometrium or support the adhesion by down regulating or up regulating expression of genes involved in adhesion/invasion.[112]

Moreover, miRNA as miR-183/96/182 seems to play a key role in circadian rhythm.[113]

Evolution

[edit]

miRNAs are well conserved in both plants and animals, and are thought to be a vital and evolutionarily ancient component of gene regulation.[114][115][116][117][118] While core components of the microRNA pathway are conserved between plants and animals, miRNA repertoires in the two kingdoms appear to have emerged independently with different primary modes of action.[119][120]

microRNAs are useful phylogenetic markers because of their apparently low rate of evolution.[121] microRNAs' origin as a regulatory mechanism developed from previous RNAi machinery that was initially used as a defense against exogenous genetic material such as viruses.[122] Their origin may have permitted the development of morphological innovation, and by making gene expression more specific and 'fine-tunable', permitted the genesis of complex organs[123] and perhaps, ultimately, complex life.[118] Rapid bursts of morphological innovation are generally associated with a high rate of microRNA accumulation.[121][123]

New microRNAs are created in multiple ways. Novel microRNAs can originate from the random formation of hairpins in "non-coding" sections of DNA (i.e. introns or intergene regions), but also by the duplication and modification of existing microRNAs.[124] microRNAs can also form from inverted duplications of protein-coding sequences, which allows for the creation of a foldback hairpin structure.[125] The rate of evolution (i.e. nucleotide substitution) in recently originated microRNAs is comparable to that elsewhere in the non-coding DNA, implying evolution by neutral drift; however, older microRNAs have a much lower rate of change (often less than one substitution per hundred million years),[118] suggesting that once a microRNA gains a function, it undergoes purifying selection.[124] Individual regions within an miRNA gene face different evolutionary pressures, where regions that are vital for processing and function have higher levels of conservation.[126] At this point, a microRNA is rarely lost from an animal's genome,[118] although newer microRNAs (thus presumably non-functional) are frequently lost.[124] In Arabidopsis thaliana, the net flux of miRNA genes has been predicted to be between 1.2 and 3.3 genes per million years.[127] This makes them a valuable phylogenetic marker, and they are being looked upon as a possible solution to outstanding phylogenetic problems such as the relationships of arthropods.[128] On the other hand, in multiple cases microRNAs correlate poorly with phylogeny, and it is possible that their phylogenetic concordance largely reflects a limited sampling of microRNAs.[129]

microRNAs feature in the genomes of most eukaryotic organisms, from the brown algae[130] to the animals. However, the difference in how these microRNAs function and the way they are processed suggests that microRNAs arose independently in plants and animals.[131]

Focusing on the animals, the genome of Mnemiopsis leidyi[132] appears to lack recognizable microRNAs, as well as the nuclear proteins Drosha and Pasha, which are critical to canonical microRNA biogenesis. It is the only animal thus far reported to be missing Drosha. MicroRNAs play a vital role in the regulation of gene expression in all non-ctenophore animals investigated thus far except for Trichoplax adhaerens, the first known member of the phylum Placozoa.[133]

Across all species, in excess of 5000 different miRNAs had been identified by March 2010.[134] Whilst short RNA sequences (50 – hundreds of base pairs) of a broadly comparable function occur in bacteria, bacteria lack true microRNAs.[135]

Experimental detection and manipulation

[edit]

While researchers focused on miRNA expression in physiological and pathological processes, various technical variables related to microRNA isolation emerged. The stability of stored miRNA samples has been questioned.[77] microRNAs degrade much more easily than mRNAs, partly due to their length, but also because of ubiquitously present RNases. This makes it necessary to cool samples on ice and use RNase-free equipment.[136]

microRNA expression can be quantified in a two-step polymerase chain reaction process of modified RT-PCR followed by quantitative PCR. Variations of this method achieve absolute or relative quantification.[137] miRNAs can also be hybridized to microarrays, slides or chips with probes to hundreds or thousands of miRNA targets, so that relative levels of miRNAs can be determined in different samples.[138] microRNAs can be both discovered and profiled by high-throughput sequencing methods (microRNA sequencing).[139] The activity of an miRNA can be experimentally inhibited using a locked nucleic acid (LNA) oligo, a Morpholino oligo[140][141] or a 2'-O-methyl RNA oligo.[142] A specific miRNA can be silenced by a complementary antagomir. microRNA maturation can be inhibited at several points by steric-blocking oligos.[143] The miRNA target site of an mRNA transcript can also be blocked by a steric-blocking oligo.[144] For the "in situ" detection of miRNA, LNA[145] or Morpholino[146] probes can be used. The locked conformation of LNA results in enhanced hybridization properties and increases sensitivity and selectivity, making it ideal for detection of short miRNA.[147]

High-throughput quantification of miRNAs is error prone, for the larger variance (compared to mRNAs) that comes with methodological problems. mRNA-expression is therefore often analyzed to check for miRNA-effects in their levels (e.g. in[148]). Databases can be used to pair mRNA- and miRNA-data that predict miRNA-targets based on their base sequence.[149][150] While this is usually done after miRNAs of interest have been detected (e. g. because of high expression levels), ideas for analysis tools that integrate mRNA- and miRNA-expression information have been proposed.[151][152]

Human and animal diseases

[edit]

Just as miRNA is involved in the normal functioning of eukaryotic cells, so has dysregulation of miRNA been associated with disease. A manually curated, publicly available database, miR2Disease, documents known relationships between miRNA dysregulation and human disease.[153]

Inherited diseases

[edit]

A mutation in the seed region of miR-96 causes hereditary progressive hearing loss.[154]

A mutation in the seed region of miR-184 causes hereditary keratoconus with anterior polar cataract.[155]

Deletion of the miR-17~92 cluster causes skeletal and growth defects.[156]

Cancer

[edit]
Role of miRNA in a cancer cell

The first human disease known to be associated with miRNA deregulation was chronic lymphocytic leukemia.[157] Many other miRNAs also have links with cancer and accordingly are sometimes referred to as "oncomirs".[158] In malignant B cells miRNAs participate in pathways fundamental to B cell development like B-cell receptor (BCR) signalling, B-cell migration/adhesion, cell-cell interactions in immune niches and the production and class-switching of immunoglobulins. MiRNAs influence B cell maturation, generation of pre-, marginal zone, follicular, B1, plasma and memory B cells.[159]

Another role for miRNA in cancers is to use their expression level for prognosis. In NSCLC samples, low miR-324a levels may serve as an indicator of poor survival.[160] Either high miR-185 or low miR-133b levels may correlate with metastasis and poor survival in colorectal cancer.[161]

Furthermore, specific miRNAs may be associated with certain histological subtypes of colorectal cancer. For instance, expression levels of miR-205 and miR-373 have been shown to be increased in mucinous colorectal cancers and mucin-producing Ulcerative Colitis-associated colon cancers, but not in sporadic colonic adenocarcinoma that lack mucinous components.[162] In-vitro studies suggested that miR-205 and miR-373 may functionally induce different features of mucinous-associated neoplastic progression in intestinal epithelial cells.[162]

Hepatocellular carcinoma cell proliferation may arise from miR-21 interaction with MAP2K3, a tumor repressor gene.[163] Optimal treatment for cancer involves accurately identifying patients for risk-stratified therapy. Those with a rapid response to initial treatment may benefit from truncated treatment regimens, showing the value of accurate disease response measures. Cell-free circulating miRNAs (cimiRNAs) are highly stable in blood, are overexpressed in cancer and are quantifiable within the diagnostic laboratory. In classical Hodgkin lymphoma, plasma miR-21, miR-494, and miR-1973 are promising disease response biomarkers.[164] Circulating miRNAs have the potential to assist clinical decision making and aid interpretation of positron emission tomography combined with computerized tomography. They can be performed at each consultation to assess disease response and detect relapse.[citation needed]

MicroRNAs have the potential to be used as tools or targets for treatment of different cancers.[165] The specific microRNA, miR-506 has been found to work as a tumor antagonist in several studies. A significant number of cervical cancer samples were found to have downregulated expression of miR-506. Additionally, miR-506 works to promote apoptosis of cervical cancer cells, through its direct target hedgehog pathway transcription factor, Gli3.[166][167]

DNA repair and cancer

[edit]

Many miRNAs can directly target and inhibit cell cycle genes to control cell proliferation. A new strategy for tumor treatment is to inhibit tumor cell proliferation by repairing the defective miRNA pathway in tumors.[168] Cancer is caused by the accumulation of mutations from either DNA damage or uncorrected errors in DNA replication.[169] Defects in DNA repair cause the accumulation of mutations, which can lead to cancer.[170] Several genes involved in DNA repair are regulated by microRNAs.[171]

Germline mutations in DNA repair genes cause only 2–5% of colon cancer cases.[172] However, altered expression of microRNAs, causing DNA repair deficiencies, are frequently associated with cancers and may be an important causal factor. Among 68 sporadic colon cancers with reduced expression of the DNA mismatch repair protein MLH1, most were found to be deficient due to epigenetic methylation of the CpG island of the MLH1 gene.[173] However, up to 15% of MLH1-deficiencies in sporadic colon cancers appeared to be due to over-expression of the microRNA miR-155, which represses MLH1 expression.[174]

In 29–66%[175][176] of glioblastomas, DNA repair is deficient due to epigenetic methylation of the MGMT gene, which reduces protein expression of MGMT. However, for 28% of glioblastomas, the MGMT protein is deficient, but the MGMT promoter is not methylated.[175] In glioblastomas without methylated MGMT promoters, the level of microRNA miR-181d is inversely correlated with protein expression of MGMT and the direct target of miR-181d is the MGMT mRNA 3'UTR (the three prime untranslated region of MGMT mRNA).[175] Thus, in 28% of glioblastomas, increased expression of miR-181d and reduced expression of DNA repair enzyme MGMT may be a causal factor.

HMGA proteins (HMGA1a, HMGA1b and HMGA2) are implicated in cancer, and expression of these proteins is regulated by microRNAs. HMGA expression is almost undetectable in differentiated adult tissues, but is elevated in many cancers. HMGA proteins are polypeptides of ~100 amino acid residues characterized by a modular sequence organization. These proteins have three highly positively charged regions, termed AT hooks, that bind the minor groove of AT-rich DNA stretches in specific regions of DNA. Human neoplasias, including thyroid, prostatic, cervical, colorectal, pancreatic and ovarian carcinomas, show a strong increase of HMGA1a and HMGA1b proteins.[177] Transgenic mice with HMGA1 targeted to lymphoid cells develop aggressive lymphoma, showing that high HMGA1 expression is associated with cancers and that HMGA1 can act as an oncogene.[178] HMGA2 protein specifically targets the promoter of ERCC1, thus reducing expression of this DNA repair gene.[179] ERCC1 protein expression was deficient in 100% of 47 evaluated colon cancers (though the extent to which HGMA2 was involved is not known).[180]

Single Nucleotide polymorphisms (SNPs) can alter the binding of miRNAs on 3'UTRs for example the case of hsa-mir181a and hsa-mir181b on the CDON tumor suppressor gene.[181]

Heart disease

[edit]

The global role of miRNA function in the heart has been addressed by conditionally inhibiting miRNA maturation in the murine heart. This revealed that miRNAs play an essential role during its development.[182][183] miRNA expression profiling studies demonstrate that expression levels of specific miRNAs change in diseased human hearts, pointing to their involvement in cardiomyopathies.[184][185][186] Furthermore, animal studies on specific miRNAs identified distinct roles for miRNAs both during heart development and under pathological conditions, including the regulation of key factors important for cardiogenesis, the hypertrophic growth response and cardiac conductance.[183][187][188][189][190] Another role for miRNA in cardiovascular diseases is to use their expression levels for diagnosis, prognosis or risk stratification.[191] miRNA's in animal models have also been linked to cholesterol metabolism and regulation.

miRNA-712

[edit]

Murine microRNA-712 is a potential biomarker (i.e. predictor) for atherosclerosis, a cardiovascular disease of the arterial wall associated with lipid retention and inflammation.[192] Non-laminar blood flow also correlates with development of atherosclerosis as mechanosenors of endothelial cells respond to the shear force of disturbed flow (d-flow).[193] A number of pro-atherogenic genes including matrix metalloproteinases (MMPs) are upregulated by d-flow,[193] mediating pro-inflammatory and pro-angiogenic signals. These findings were observed in ligated carotid arteries of mice to mimic the effects of d-flow. Within 24 hours, pre-existing immature miR-712 formed mature miR-712 suggesting that miR-712 is flow-sensitive.[193] Coinciding with these results, miR-712 is also upregulated in endothelial cells exposed to naturally occurring d-flow in the greater curvature of the aortic arch.[193]

Origin

[edit]

Pre-mRNA sequence of miR-712 is generated from the murine ribosomal RN45s gene at the internal transcribed spacer region 2 (ITS2).[193] XRN1 is an exonuclease that degrades the ITS2 region during processing of RN45s.[193] Reduction of XRN1 under d-flow conditions therefore leads to the accumulation of miR-712.[193]

Mechanism

[edit]

MiR-712 targets tissue inhibitor of metalloproteinases 3 (TIMP3).[193] TIMPs normally regulate activity of matrix metalloproteinases (MMPs) which degrade the extracellular matrix (ECM). Arterial ECM is mainly composed of collagen and elastin fibers, providing the structural support and recoil properties of arteries.[194] These fibers play a critical role in regulation of vascular inflammation and permeability, which are important in the development of atherosclerosis.[195] Expressed by endothelial cells, TIMP3 is the only ECM-bound TIMP.[194] A decrease in TIMP3 expression results in an increase of ECM degradation in the presence of d-flow. Consistent with these findings, inhibition of pre-miR712 increases expression of TIMP3 in cells, even when exposed to turbulent flow.[193]

TIMP3 also decreases the expression of TNFα (a pro-inflammatory regulator) during turbulent flow.[193] Activity of TNFα in turbulent flow was measured by the expression of TNFα-converting enzyme (TACE) in blood. TNFα decreased if miR-712 was inhibited or TIMP3 overexpressed,[193] suggesting that miR-712 and TIMP3 regulate TACE activity in turbulent flow conditions.

Anti-miR-712 effectively suppresses d-flow-induced miR-712 expression and increases TIMP3 expression.[193] Anti-miR-712 also inhibits vascular hyperpermeability, thereby significantly reducing atherosclerosis lesion development and immune cell infiltration.[193]

Human homolog microRNA-205

[edit]

The human homolog of miR-712 was found on the RN45s homolog gene, which maintains similar miRNAs to mice.[193] MiR-205 of humans share similar sequences with miR-712 of mice and is conserved across most vertebrates.[193] MiR-205 and miR-712 also share more than 50% of the cell signaling targets, including TIMP3.[193]

When tested, d-flow decreased the expression of XRN1 in humans as it did in mice endothelial cells, indicating a potentially common role of XRN1 in humans.[193]

Kidney disease

[edit]

Targeted deletion of Dicer in the FoxD1-derived renal progenitor cells in a murine model resulted in a complex renal phenotype including expansion of nephron progenitors, fewer renin cells, smooth muscle arterioles, progressive mesangial loss and glomerular aneurysms.[196] High throughput whole transcriptome profiling of the FoxD1-Dicer knockout mouse model revealed ectopic upregulation of pro-apoptotic gene, Bcl2L11 (Bim) and dysregulation of the p53 pathway with increase in p53 effector genes including Bax, Trp53inp1, Jun, Cdkn1a, Mmp2, and Arid3a. p53 protein levels remained unchanged, suggesting that FoxD1 stromal miRNAs directly repress p53-effector genes. Using a lineage tracing approach followed by Fluorescent-activated cell sorting, miRNA profiling of the FoxD1-derived cells not only comprehensively defined the transcriptional landscape of miRNAs that are critical for vascular development, but also identified key miRNAs that are likely to modulate the renal phenotype in its absence. These miRNAs include miRs-10a, 18a, 19b, 24, 30c, 92a, 106a, 130a, 152, 181a, 214, 222, 302a, 370, and 381 that regulate Bcl2L11 (Bim) and miRs-15b, 18a, 21, 30c, 92a, 106a, 125b-5p, 145, 214, 222, 296-5p and 302a that regulate p53-effector genes. Consistent with the profiling results, ectopic apoptosis was observed in the cellular derivatives of the FoxD1 derived progenitor lineage and reiterates the importance of renal stromal miRNAs in cellular homeostasis.[196]

Nervous system

[edit]

MiRNAs are crucial for the healthy development and function of the nervous system.[197] Previous studies demonstrate that miRNAs can regulate neuronal differentiation and maturation at various stages.[198] MiRNAs also play important roles in synaptic development[199] (such as dendritogenesis or spine morphogenesis) and synaptic plasticity[200] (contributing to learning and memory). Elimination of miRNA formation in mice by experimental silencing of Dicer has led to pathological outcomes, such as reduced neuronal size, motor abnormalities (when silenced in striatal neurons[201]), and neurodegeneration (when silenced in forebrain neurons[202]). Altered miRNA expression has been found in neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease, and Huntington's disease[203]) as well as many psychiatric disorders (including epilepsy,[204] schizophrenia, major depression, bipolar disorder, and anxiety disorders[205][206][207]).

Stroke

[edit]

According to the Center for Disease Control and Prevention, Stroke is one of the leading causes of death and long-term disability in America. 87% of the cases are ischemic strokes, which results from blockage in the artery of the brain that carries oxygen-rich blood. The obstruction of the blood flow means the brain cannot receive necessary nutrients, such as oxygen and glucose, and remove wastes, such as carbon dioxide.[208][209] miRNAs plays a role in posttranslational gene silencing by targeting genes in the pathogenesis of cerebral ischemia, such as the inflammatory, angiogenesis, and apoptotic pathway.[210] 

Alcoholism

[edit]

The vital role of miRNAs in gene expression is significant to addiction, specifically alcoholism.[211] Chronic alcohol abuse results in persistent changes in brain function mediated in part by alterations in gene expression.[211] miRNA global regulation of many downstream genes deems significant regarding the reorganization or synaptic connections or long term neural adaptations involving the behavioral change from alcohol consumption to withdrawal and/or dependence.[212] Up to 35 different miRNAs have been found to be altered in the alcoholic post-mortem brain, all of which target genes that include the regulation of the cell cycle, apoptosis, cell adhesion, nervous system development and cell signaling.[211] Altered miRNA levels were found in the medial prefrontal cortex of alcohol-dependent mice, suggesting the role of miRNA in orchestrating translational imbalances and the creation of differentially expressed proteins within an area of the brain where complex cognitive behavior and decision making likely originate.[213]

miRNAs can be either upregulated or downregulated in response to chronic alcohol use. miR-206 expression increased in the prefrontal cortex of alcohol-dependent rats, targeting the transcription factor brain-derived neurotrophic factor (BDNF) and ultimately reducing its expression. BDNF plays a critical role in the formation and maturation of new neurons and synapses, suggesting a possible implication in synapse growth/synaptic plasticity in alcohol abusers.[214] miR-155, important in regulating alcohol-induced neuroinflammation responses, was found to be upregulated, suggesting the role of microglia and inflammatory cytokines in alcohol pathophysiology.[215] Downregulation of miR-382 was found in the nucleus accumbens, a structure in the basal forebrain significant in regulating feelings of reward that power motivational habits. miR-382 is the target for the dopamine receptor D1 (DRD1), and its overexpression results in the upregulation of DRD1 and delta fosB, a transcription factor that activates a series of transcription events in the nucleus accumbens that ultimately result in addictive behaviors.[216] Alternatively, overexpressing miR-382 resulted in attenuated drinking and the inhibition of DRD1 and delta fosB upregulation in rat models of alcoholism, demonstrating the possibility of using miRNA-targeted pharmaceuticals in treatments.[216]

Obesity

[edit]

miRNAs play crucial roles in the regulation of stem cell progenitors differentiating into adipocytes.[217] Studies to determine what role pluripotent stem cells play in adipogenesis, were examined in the immortalized human bone marrow-derived stromal cell line hMSC-Tert20.[218] Decreased expression of miR-155, miR-221, and miR-222, have been found during the adipogenic programming of both immortalized and primary hMSCs, suggesting that they act as negative regulators of differentiation. Conversely, ectopic expression of the miRNAs 155, 221, and 222 significantly inhibited adipogenesis and repressed induction of the master regulators PPARγ and CCAAT/enhancer-binding protein alpha (CEBPA).[219] This paves the way for possible genetic obesity treatments.

Another class of miRNAs that regulate insulin resistance, obesity, and diabetes, is the let-7 family. Let-7 accumulates in human tissues during the course of aging.[220] When let-7 was ectopically overexpressed to mimic accelerated aging, mice became insulin-resistant, and thus more prone to high fat diet-induced obesity and diabetes.[221] In contrast when let-7 was inhibited by injections of let-7-specific antagomirs, mice become more insulin-sensitive and remarkably resistant to high fat diet-induced obesity and diabetes. Not only could let-7 inhibition prevent obesity and diabetes, it could also reverse and cure the condition.[222] These experimental findings suggest that let-7 inhibition could represent a new therapy for obesity and type 2 diabetes.

Hemostasis

[edit]

miRNAs also play crucial roles in the regulation of complex enzymatic cascades including the hemostatic blood coagulation system.[223] Large scale studies of functional miRNA targeting have recently uncovered rationale therapeutic targets in the hemostatic system.[224][225] They have been directly linked to Calcium homeostasis in the endoplasmic reticulum, which is critical in cell differentiation in early development.[226]

Plants

[edit]

miRNAs are considered to be key regulators of many developmental, homeostatic, and immune processes in plants.[227] Their roles in plant development include shoot apical meristem development, leaf growth, flower formation, seed production, or root expansion.[228][229][230][231] In addition, they play a complex role in responses to various abiotic stresses comprising heat stress, low-temperature stress, drought stress, light stress, or gamma radiation exposure.[227]

Viruses

[edit]

Viral microRNAs play an important role in the regulation of gene expression of viral and/or host genes to benefit the virus. Hence, miRNAs play a key role in host–virus interactions and pathogenesis of viral diseases.[232][233] The expression of transcription activators by human herpesvirus-6 DNA is believed to be regulated by viral miRNA.[234]

Target prediction

[edit]

miRNAs can bind to target messenger RNA (mRNA) transcripts of protein-coding genes and negatively control their translation or cause mRNA degradation. It is of key importance to identify the miRNA targets accurately.[235] A comparison of the predictive performance of eighteen in silico algorithms is available.[236] Large scale studies of functional miRNA targeting suggest that many functional miRNAs can be missed by target prediction algorithms.[224]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
MicroRNAs (miRNAs) are small, non-coding RNA molecules, typically 19–25 nucleotides in length, that regulate gene expression post-transcriptionally in eukaryotes by binding to target messenger RNAs (mRNAs).[1] They primarily target the 3' untranslated region (UTR) of mRNAs through base-pairing interactions, leading to translational repression, mRNA destabilization, or degradation, thereby fine-tuning protein production from thousands of genes.[2] First identified in 1993 with the discovery of lin-4 in the nematode Caenorhabditis elegans, this breakthrough was recognized by the 2024 Nobel Prize in Physiology or Medicine awarded to Victor Ambros and Gary Ruvkun.[3] miRNAs represent an ancient and evolutionarily conserved regulatory mechanism present in plants, animals, and other organisms.[2] The biogenesis of miRNAs follows a canonical pathway in most cases, beginning with transcription by RNA polymerase II into long primary miRNA (pri-miRNA) transcripts in the nucleus, which fold into stem-loop structures.[2] These pri-miRNAs are then cleaved by the microprocessor complex—consisting of the RNase III enzyme Drosha and the double-stranded RNA-binding protein DGCR8—into precursor miRNAs (pre-miRNAs), approximately 70 nucleotides long.[1] The pre-miRNAs are exported to the cytoplasm via Exportin-5 and Ran-GTP, where they are further processed by the RNase III enzyme Dicer into a mature miRNA duplex; one strand of this duplex is subsequently loaded into the Argonaute (AGO) protein within the RNA-induced silencing complex (RISC), which mediates target recognition and silencing.[2] Non-canonical pathways also exist, such as Drosha-independent mirtron biogenesis or Dicer-independent processing by AGO2, allowing for diverse miRNA production in specific contexts.[2] miRNAs exert profound influence on biological processes, including embryonic development, cell differentiation, proliferation, and apoptosis, by modulating networks of target genes essential for tissue homeostasis and organismal patterning.[1] Dysregulation of miRNAs contributes to numerous diseases, notably cancers—where certain miRNAs act as oncogenes or tumor suppressors, such as miR-15a and miR-16-1 in chronic lymphocytic leukemia—and infectious or inflammatory conditions like hepatitis C virus replication via miR-122.[1] Beyond intracellular roles, miRNAs are secreted in extracellular vesicles like exosomes, facilitating cell-to-cell communication and serving as circulating biomarkers for diagnostics; their therapeutic potential is being explored through mimics, inhibitors, and antagomirs to restore gene regulation in pathological states.[2] More than 2,600 mature miRNAs have been annotated in humans (miRBase release 22, 2018),[4] underscoring their pervasive impact on the genome.[1]

Discovery and History

Key Milestones

The earliest indications of RNA silencing emerged in plant systems during the 1960s and 1970s, where phenomena such as RNA-directed RNA polymerization were observed, hinting at mechanisms for gene regulation through nucleic acid interactions. In the 1990s, forward genetic screens in the nematode Caenorhabditis elegans for mutants affecting developmental timing, known as heterochronic genes, provided crucial insights into non-protein-coding regulators of gene expression. A pivotal milestone occurred in 1993 when Victor Ambros and colleagues identified the lin-4 gene in C. elegans, revealing it encoded small non-coding RNAs of approximately 22 nucleotides that exhibited antisense complementarity to the 3' untranslated region of the lin-14 mRNA, thereby regulating its translation without encoding a protein.[5] This discovery marked the first identification of what would later be classified as a microRNA (miRNA). In 2000, Gary Ruvkun's team reported the let-7 gene, another small RNA in C. elegans that controlled late-stage developmental timing by targeting lin-41, and demonstrated its sequence conservation across diverse animal species, establishing miRNAs as a widespread class of regulators. The extension of miRNA research to mammals came in 2001, when multiple groups, including that of Thomas Tuschl, cloned small RNAs from human HeLa cells and other sources, identifying over 200 novel miRNA genes and confirming their presence and conservation in humans. This cloning approach rapidly expanded the known miRNA repertoire and underscored their evolutionary conservation. In recognition of foundational work on RNA interference (RNAi), which shares mechanistic overlap with miRNA pathways through double-stranded RNA triggers, Andrew Fire and Craig Mello were awarded the 2006 Nobel Prize in Physiology or Medicine for their 1998 discovery of RNAi in C. elegans.[6] For the discovery of microRNAs and their role in gene regulation, Victor Ambros and Gary Ruvkun were awarded the 2024 Nobel Prize in Physiology or Medicine.[3] Following these events, biogenesis pathways for miRNAs were elucidated in the early 2000s, revealing nuclear and cytoplasmic processing steps essential for their maturation.[1]

Foundational Discoveries

The foundational discoveries in microRNA (miRNA) research began with the identification of lin-4 in Caenorhabditis elegans, a small non-coding RNA that regulates developmental timing through post-transcriptional repression of the LIN-14 protein. In 1993, researchers observed that lin-4, a 22-nucleotide RNA, did not encode a protein but instead bound to complementary sequences in the 3' untranslated region (UTR) of the lin-14 mRNA, reducing LIN-14 protein levels without significantly altering mRNA abundance, thus establishing a novel mechanism of gene regulation at the translational level. This finding challenged the prevailing view that gene expression was primarily controlled at the transcriptional level and highlighted the role of small RNAs in temporal patterning during larval development. Building on lin-4, the discovery of let-7 in 2000 further solidified the concept of miRNAs as key regulators of developmental progression in C. elegans. Let-7, a 21-nucleotide RNA, was found to temporally repress the LIN-41 protein, ensuring the proper transition from larval to adult stages by inhibiting premature differentiation. Like lin-4, let-7 exerted its effects through imperfect base-pairing with target mRNAs, leading to translational repression rather than mRNA degradation, and its expression pattern was temporally restricted to late larval stages. These observations demonstrated that miRNAs form a class of endogenous small RNAs distinct from small interfering RNAs (siRNAs), which primarily mediate RNA interference from exogenous double-stranded RNA and typically cause mRNA cleavage via perfect complementarity. The distinction emphasized miRNAs' role in fine-tuning endogenous gene expression through partial complementarity and translational control.[7] A major breakthrough occurred in 2001–2002 with the development of cloning strategies that systematically identified hundreds of miRNAs across diverse species, transforming miRNAs from curiosities into a widespread regulatory mechanism. Techniques involving size-fractionation of small RNAs, ligation to adapters, and high-throughput sequencing or cloning revealed over 100 miRNAs in C. elegans, Drosophila melanogaster, and humans, many of which were conserved in sequence and function. For instance, one study cloned 55 novel miRNAs from C. elegans and related species, while others identified 218 in humans and mice, demonstrating that miRNAs constitute a conserved gene family numbering in the hundreds per genome. These discoveries precipitated a paradigm shift in genomics, redirecting focus from protein-coding genes to non-coding RNAs as central players in gene regulation. Prior to miRNA cloning, genomic efforts emphasized coding sequences, but the abundance and evolutionary conservation of miRNAs—evidenced by sequence homology of let-7 and lin-4 orthologs from nematodes to humans—revealed a pervasive layer of post-transcriptional control influencing development, differentiation, and disease. This realization, supported by bioinformatics predictions of thousands of conserved miRNA targets, underscored that non-coding RNAs could modulate up to 60% of human genes, fundamentally altering models of regulatory networks. Early homology searches confirmed that dozens of miRNAs, including let-7 family members, shared near-identical seed sequences across bilaterians, affirming their ancient origins and broad regulatory impact.

Nomenclature and Classification

Naming Conventions

miRBase serves as the central repository for microRNA (miRNA) annotation, providing standardized sequences, nomenclature, and data for thousands of miRNAs across species, with version 22 released in 2018 incorporating over 38,000 entries and ongoing maintenance to reflect new discoveries.[4] The nomenclature system originated from guidelines established by a working group of researchers in 2003, which introduced a uniform framework to distinguish miRNAs from other small RNAs and ensure consistent naming based on experimental validation, such as cloning or expression evidence.[8] These initial rules have evolved through subsequent miRBase updates, incorporating refinements for high-throughput sequencing data while maintaining core principles for precursor and mature miRNA identification.[9] Under current conventions, precursor miRNAs (pri- and pre-miRNAs forming hairpin structures) are denoted with the lowercase prefix "mir-" followed by a unique numerical identifier, such as mir-21, and are italicized to indicate they are genes.[9] Mature miRNAs, the functional ~22-nucleotide products derived from one arm of the precursor, use the uppercase prefix "miR-" with the same identifier, for example miR-21, reflecting their processed form.[9][8] To specify species, a three-letter prefix based on the standard genetic code is added before the name, such as "hsa-" for Homo sapiens (human), resulting in hsa-mir-21 for the precursor and hsa-miR-21 for the mature form; this allows orthologs across species to share identifiers if sequences are highly similar.[9][8] Paralogs—duplicate genes within the same species producing identical or near-identical miRNAs—are distinguished by adding sequential suffixes like "-1" or "-2", as in hsa-mir-21-1 and hsa-mir-21-2, to denote distinct genomic loci.[9][8] Arm-specific naming further refines mature miRNA designations by appending "-5p" or "-3p" to indicate derivation from the 5' or 3' arm of the precursor hairpin, such as hsa-miR-21-5p; this became standard as sequencing revealed both arms can yield functional products, replacing earlier assumptions of dominance by one strand.[9] miRNA families are often grouped by shared seed sequences (nucleotides 2–8 of the mature miRNA), which guide target recognition, but formal naming prioritizes precursor origin over functional clustering.[9] IsomiRs—sequence variants of mature miRNAs arising from imprecise processing or editing—are not assigned unique names but are documented in miRBase with details on their deviations from the reference sequence to avoid nomenclature proliferation.[9] Novel miRNAs discovered through experimental methods, such as small RNA sequencing with validation (e.g., Northern blotting or functional assays), must be submitted to miRBase for official naming and inclusion, following updated annotation criteria that emphasize biogenesis evidence and conservation.[9][8]

miRNA Families and Types

MicroRNA (miRNA) families are defined as groups of miRNAs that share high sequence similarity, particularly in the seed region—nucleotides 2–8 at the 5′ end of the mature miRNA—which determines target specificity and functional redundancy among family members.[10] This conservation allows family members to regulate overlapping sets of messenger RNA targets, enabling coordinated control of biological processes.[11] In humans, miRNA families are annotated based on these shared seeds, with naming conventions often reflecting paralogous clusters derived from gene duplication events.[12] Prominent miRNA families include the let-7 family, which comprises multiple paralogs (e.g., let-7a to let-7g) highly conserved across species and critical for developmental timing by repressing cell proliferation genes.[13] The miR-17~92 cluster family, encompassing paralogs like miR-17, miR-18, miR-19, and miR-92, functions in cell growth and survival pathways, often exhibiting oncogenic potential through amplification in cancers.[14] Similarly, the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, miR-429) regulates epithelial-mesenchymal transition by targeting transcription factors such as ZEB1 and ZEB2, maintaining epithelial cell identity.[15] miRNAs are broadly classified into canonical and non-canonical types based on their biogenesis pathways. Canonical miRNAs depend on the RNase III enzyme Dicer for processing from precursor hairpins into mature forms, representing the majority of annotated miRNAs that integrate into the RNA-induced silencing complex (RISC) for gene regulation.[16] In contrast, non-canonical miRNAs bypass Dicer and include mirtrons, which are derived directly from introns via splicing without requiring Drosha or Dicer, producing functional miRNA-like molecules from short introns.[17] Other non-canonical types encompass endogenous small interfering RNAs (endo-siRNAs), which arise from double-stranded RNA precursors and mediate precise mRNA cleavage, and tRNA-derived small RNAs, fragments of transfer RNAs that mimic miRNA activity in silencing.[18][19] As of the latest annotations in miRBase (release 22, with ongoing updates through 2025), 2,654 mature miRNAs have been identified in humans, derived from 1,917 precursor hairpins, though expression levels vary widely across tissues.[20] However, some analyses suggest that only about 1,115 of these may represent authentic miRNAs expressed in human cells, with others potentially being degradation products or artifacts.[21] Functionally, miRNAs can be categorized as oncomiRs—those overexpressed in tumors to promote oncogenesis by repressing tumor suppressors—or tumor suppressor miRNAs, which inhibit cell proliferation and metastasis by targeting oncogenes, with examples spanning both canonical and non-canonical types.[22]

Biogenesis

Transcription of pri-miRNA

MicroRNAs are initially transcribed as primary transcripts known as pri-miRNAs in the nucleus of eukaryotic cells. These transcripts are synthesized by RNA polymerase II (Pol II), which recognizes specific promoter sequences associated with miRNA genes.00756-7)[23] Most pri-miRNAs are generated from intergenic miRNA loci, which function as independent transcriptional units located between protein-coding genes, while others are intragenic, embedded within introns of protein-coding host genes and co-transcribed with them.00045-5) In both cases, the transcription produces long primary transcripts that resemble messenger RNAs (mRNAs) in structure and processing features. The promoters driving pri-miRNA transcription are analogous to those of protein-coding genes, often featuring core elements such as TATA boxes and upstream enhancers that facilitate Pol II recruitment and initiation.[24] These regulatory sequences enable precise control over miRNA expression, allowing for tissue-specific or developmental stage-specific activation. For instance, the oncogenic transcription factor c-Myc binds to the promoter of the intergenic miR-1792 cluster—a polycistronic unit encoding six mature miRNAs (miR-17, miR-18a, miR-19a, miR-19b-1, miR-20a, and miR-92a-1)—to upregulate its transcription, promoting cell proliferation in contexts like B-cell lymphomas. Polycistronic clusters, such as miR-1792, are transcribed as a single pri-miRNA containing multiple hairpins, whereas most intergenic miRNAs arise from monocistronic transcripts with a single hairpin. Intragenic miRNAs, comprising about half of all miRNAs, lack dedicated promoters and instead rely on the host gene's transcriptional machinery, leading to coordinated expression with the host transcript.00045-5) Structurally, pri-miRNAs are capped at the 5' end with a 7-methylguanosine cap and polyadenylated at the 3' end, features that stabilize the transcripts and mimic mRNA processing. Embedded within these extended pri-miRNAs (often several kilobases long) is a characteristic imperfect stem-loop hairpin structure, typically ~60-80 nucleotides in length, which serves as the precursor for the mature miRNA.00045-5) This hairpin, with its double-stranded stem and terminal loop, is the key recognition motif for subsequent nuclear processing into pre-miRNA. Transcriptional regulation by factors like c-Myc not only amplifies miRNA output but also integrates miRNA biogenesis into broader gene regulatory networks, influencing processes such as development and oncogenesis.

Nuclear Processing

In the nucleus, primary microRNAs (pri-miRNAs), which are initially transcribed as long transcripts with hairpin structures, undergo processing by the Microprocessor complex to generate precursor miRNAs (pre-miRNAs). This complex consists of the RNase III enzyme Drosha and its cofactor DGCR8 (also known as Pasha), which together recognize and cleave the pri-miRNA at the base of the stem-loop structure. Drosha's two RNase III domains execute the cleavage, with one domain cutting the 3' strand and the other the 5' strand, producing a characteristic ~2-nucleotide 3' overhang on the pre-miRNA. DGCR8, featuring two double-stranded RNA-binding domains, stabilizes the interaction with the pri-miRNA substrate and enhances processing efficiency.[25] The cleavage by Drosha exhibits specificity for pri-miRNA hairpins featuring an imperfect double-stranded stem of approximately 22 base pairs, flanked by single-stranded regions that aid in recognition. This precise excision yields pre-miRNAs of about 60-70 nucleotides in length, which maintain the stem-loop conformation essential for subsequent steps. While most miRNAs are exported and matured in the cytoplasm, a subset of nuclear miRNAs, such as miR-320, remain and exert regulatory functions within the nucleus; for instance, miR-320 associates with Argonaute proteins to target and silence genes like POLR3D by interacting with promoter regions and reducing RNA polymerase II occupancy.[25][26] Nuclear processing is tightly regulated by cofactors that modulate Microprocessor activity in response to cellular signals. In the transforming growth factor-β (TGF-β) pathway, Smad proteins (e.g., Smad2/3) bind to specific sequences in pri-miRNA stems, recruiting Drosha and DGCR8 to enhance cleavage without altering transcription rates; this mechanism promotes maturation of miRNAs like miR-21 in a Smad4-independent manner, often in conjunction with the RNA helicase p68 (DDX5). Defects in this process, such as mutations in DGCR8, disrupt pri-miRNA cleavage and are linked to congenital disorders including DiGeorge syndrome due to impaired miRNA biogenesis.[27][28]

Cytoplasmic Maturation

In the cytoplasm, the precursor microRNA (pre-miRNA), which has been exported from the nucleus, undergoes further processing by the RNase III enzyme Dicer in complex with the double-stranded RNA-binding protein TRBP.01109-8) This complex recognizes the characteristic stem-loop structure of the pre-miRNA and cleaves the terminal loop, generating an approximately 22-nucleotide miRNA duplex consisting of the mature miRNA and its complementary passenger strand (miRNA*).00951-4) The cleavage occurs at a specific distance from the stem base, ensuring the production of duplexes with defined lengths suitable for subsequent incorporation into effector complexes.00951-4.pdf) The miRNA duplex is then unwound, and one strand—the guide strand—is preferentially selected for retention, while the passenger strand is typically discarded. In mammals, Argonaute 2 (AGO2) serves as the primary acceptor for the guide strand due to its slicer activity and compatibility with the biogenesis machinery.01351-7.pdf) The resulting mature miRNA is characterized by a 5' seed region spanning nucleotides 2–8, which is critical for target recognition and binding to messenger RNAs, and a 3' end that contributes to overall stability and functional modulation.[29] Imperfections in the pre-miRNA hairpin structure, such as mismatched base pairs or aberrant loops, trigger a quality control mechanism where Dicer and associated factors reject these substrates, preventing the accumulation of non-functional or potentially harmful products.00610-8) Although the canonical pathway relies on Dicer, certain miRNAs, such as miR-451, follow non-canonical routes where AGO2 directly cleaves the pre-miRNA using its endogenous slicer activity, bypassing Dicer entirely.30113-1) This Dicer-independent processing is particularly prominent in specific cell types like erythrocytes and highlights the flexibility of miRNA maturation to accommodate specialized regulatory needs.30113-1)

Export Mechanisms

The precursor miRNA (pre-miRNA), a ~60-70 nucleotide hairpin structure produced in the nucleus, is actively transported to the cytoplasm to enable further maturation. This nuclear export is primarily mediated by Exportin-5 (XPO5), a member of the karyopherin family of transport receptors, which recognizes the characteristic double-stranded stem-loop architecture of pre-miRNA in a sequence-independent manner.[30] XPO5 forms a ternary complex with pre-miRNA and the GTP-bound form of the small GTPase Ran (Ran-GTP) in the nucleus, facilitating translocation through the nuclear pore complex (NPC) via interactions with nucleoporins. The binding specificity of XPO5 relies on the pre-miRNA's structural features, particularly the 2-nucleotide 3' overhang generated by prior nuclear processing, which engages key residues in XPO5's HEAT-repeat domains for stable association.[31][32] This overhang, along with the apical loop and stem, ensures selective export over other RNAs, preventing off-target transport.[33] The directionality of this export is governed by the Ran-GTP gradient across the nuclear envelope: high nuclear Ran-GTP promotes complex assembly, while in the cytoplasm, GTP hydrolysis to Ran-GDP—catalyzed by Ran GTPase-activating protein (RanGAP)—triggers cargo release, ensuring unidirectional transport.[32] Dysregulation of this process, such as through inactivating mutations in XPO5 observed in microsatellite instability-associated cancers, leads to reduced pre-miRNA export and global miRNA downregulation, contributing to oncogenesis.[34][35] Although XPO5/Ran-GTP represents the canonical pathway, alternative mechanisms exist for certain miRNA precursors; for instance, some 5'-capped pri-miRNAs are exported via Exportin-1 (also known as CRM1) in a Ran-GTP-dependent manner, bypassing the standard pre-miRNA route.[36][37]

Variations in Plants

Plant microRNAs (miRNAs) differ from their animal counterparts in biogenesis and function, particularly through enhanced sequence complementarity to target mRNAs that promotes direct cleavage rather than primarily translational repression.[38] This near-perfect base-pairing, especially at the 5' end, enables plant miRNAs to guide the RNA-induced silencing complex (RISC) to slice target transcripts efficiently, a mechanism less common in animals where imperfect pairing predominates.[38] Transcription of primary miRNA (pri-miRNA) transcripts in plants occurs via RNA polymerase II, with most MIR genes situated in intergenic regions and incorporating promoters that respond to abiotic stresses like drought, salinity, and nutrient deprivation.[39] These stress-responsive elements allow dynamic regulation of miRNA expression to adapt to environmental challenges.[39] Processing of pri-miRNAs in plants is confined to the nucleus and executed solely by the Dicer-like 1 (DCL1) enzyme, which sequentially cleaves the pri-miRNA into the precursor miRNA (pre-miRNA) and then the mature miRNA duplex, without a distinct Drosha homolog as in animals.[38] DCL1 activity is supported by accessory proteins such as HYPONASTIC LEAVES 1 (HYL1) and SERRATE (SE), ensuring precise hairpin formation and accurate excision.[38] Following processing, the miRNA duplex is exported to the cytoplasm by HASTY (HST), the plant ortholog of Exportin-5, facilitating subsequent loading into Argonaute proteins for RISC assembly.[40] In the model plant Arabidopsis thaliana, 428 mature miRNAs have been annotated, many of which are conserved across plant species and essential for regulating developmental transitions, such as leaf morphogenesis and flowering, as well as bolstering defense against biotic and abiotic stresses.[20][38][41] These miRNAs, including families like miR156 and miR393, exemplify the pathway's role in maintaining homeostasis and adaptability.[38]

Structure and Action

Mature miRNA Structure

Mature microRNAs (miRNAs) are single-stranded, non-coding RNA molecules that function as key regulators of gene expression. They typically range in length from 19 to 25 nucleotides, with a predominant size of approximately 22 nucleotides, and possess a 5' phosphate group and a 2-nucleotide 3' overhang resulting from RNase III-mediated cleavage during their maturation from precursor miRNAs (pre-miRNAs). These structural hallmarks enable mature miRNAs to integrate into effector complexes and recognize target transcripts efficiently.[42] A defining feature of mature miRNAs is the seed region, spanning nucleotides 2 to 8 from the 5' end, which mediates base-pairing with complementary sequences in the 3' untranslated region (UTR) of target mRNAs. The thermodynamic stability of the seed:mRNA duplex is crucial for effective targeting, as higher stability correlates with enhanced silencing efficacy and reduced off-target effects. Variations in this region's pairing, such as mismatches or bulges, can modulate regulatory outcomes without compromising overall function.[42][43] Mature miRNAs often exhibit post-processing modifications that influence their stability and activity. For instance, non-templated uridylation at the 3' end, catalyzed by terminal uridylyltransferases like TUT1, can stabilize certain miRNAs by preventing exonucleolytic degradation. In plants, a prominent modification is 2'-O-methylation at the 3' terminal ribose, which shields miRNAs from 3'-5' exoribonucleases and extends their lifespan. Additionally, isomiRs—isoforms generated by imprecise Drosha or Dicer cleavage—introduce heterogeneity in length (e.g., 5' or 3' trimming) or sequence (e.g., nucleotide additions or substitutions), potentially shifting the seed region and expanding or altering target repertoires.[44][45][46]

Integration into RISC

The integration of mature microRNA (miRNA) into the RNA-induced silencing complex (RISC) begins with the binding of the miRNA duplex to Argonaute (AGO) proteins, the core effectors of RISC in mammals, where AGO1–4 facilitate the assembly.[47] During this loading process, the miRNA duplex is captured by AGO, followed by the ejection of the passenger strand, leaving the guide strand anchored in the AGO protein to form the functional miRISC. This strand selection favors the strand with lower thermodynamic stability at its 5' end, typically resulting in preferential incorporation of the 5p arm over the 3p arm, though both can load depending on sequence features and AGO subtype preferences. Recent studies have revealed post-translational modifications on AGO proteins that modulate RISC efficiency (as of 2025).[48][49] The core components of miRISC include AGO proteins complexed with GW182 family proteins, which are essential for miRNA-mediated translational repression and mRNA deadenylation in somatic cells.[50] In contrast, the PIWI clade of Argonaute proteins, such as PIWIL1–4, assembles distinct RISC-like complexes primarily in the germline, where they interact with PIWI-interacting RNAs (piRNAs) rather than miRNAs for transposon silencing. Efficiency of miRNA loading is enhanced by the RISC-loading complex (RLC), which comprises Dicer and TRBP (TAR RNA-binding protein), bridging miRNA maturation and RISC assembly to ensure precise duplex handover to AGO2, the predominant slicer-competent AGO in mammals.[51] RISC activation involves ATP-dependent conformational changes in AGO proteins, mediated by chaperone machinery including Hsc70 and Hsp90, which facilitate duplex unwinding and stable guide strand accommodation without participating in passenger strand ejection.[52] This energy-dependent step is crucial for pathways requiring high-fidelity loading, such as in response to cellular stress or specific miRNA subsets, ensuring RISC readiness for gene regulation.[53]

Targeting and Silencing Mechanisms

MicroRNAs (miRNAs), upon integration into the RNA-induced silencing complex (RISC), primarily recognize target messenger RNAs (mRNAs) through base-pairing interactions involving the miRNA seed region, spanning nucleotides 2 to 8 at the 5' end. This seed sequence enables complementary matching to miRNA response elements (MREs) in the target mRNA, with perfect seed pairing conferring high specificity and affinity, while imperfect pairing allows for broader regulatory potential.[54][55] Seminal studies have established that even single nucleotide mismatches in the seed can abolish targeting, underscoring its critical role in specificity.[55] Target binding sites are predominantly located in the 3' untranslated region (UTR) of mRNAs, where accessibility is enhanced by A/U-rich sequences or proximity to other sites (within ~50 nucleotides), amplifying repression through cooperative RISC recruitment.[55] Sites can also occur in the 5' UTR or coding sequence (CDS), though these are less common and often exert weaker effects due to structural constraints or ribosomal interference.[56] Multiple conserved sites on a single mRNA can synergistically boost silencing efficiency, with models indicating that site spacing and number directly correlate with repression strength.[55] Silencing occurs via distinct modes depending on complementarity and organism. In plants, near-perfect base-pairing across the miRNA triggers endonucleolytic cleavage of the target mRNA by Argonaute (AGO) proteins, leading to rapid degradation.[57] In animals, imperfect seed matching predominates, initiating translational repression by inhibiting translation initiation—often through disruption of the eIF4E-eIF4G-PABP interaction—or promoting mRNA destabilization via deadenylation by the CCR4-NOT complex, followed by decapping and exonucleolytic decay.[58][59] While AGO2 can mediate cleavage in animals with extensive complementarity, this is rare compared to decay pathways, which account for the majority (~70-90%) of repression.[60] Off-target effects arise from unintended repression of mRNAs with partial seed complementarity, mimicking miRNA-like silencing and contributing to transcriptome-wide impacts, as observed in early siRNA studies adapted to miRNAs. These effects can be modulated by RNA-binding proteins (RBPs) that alter site accessibility, potentially buffering or enhancing repression. Recent studies have also identified nuclear miRISC instances for direct chromatin regulation (as of 2025).[61][62] Quantitative models reveal that repression efficiency per site is typically modest, with direct measurements showing 5-15% reduction in mRNA stability for 3' UTR sites, though multiple sites can cumulatively achieve 50-70% overall repression under physiological conditions.[63][60] Efficacy depends on factors like miRNA concentration, target abundance, and binding affinity, with biochemical assays indicating that seed-matched sites occupy RISC with dissociation constants (K_d) in the nanomolar range, enabling pervasive but weak regulation across >60% of human genes.[64][60]

Stability and Turnover

miRNA Degradation Pathways

Mature microRNAs (miRNAs) exhibit varying degrees of stability within cells, with turnover regulated by multiple degradation pathways that ensure precise control over gene silencing activity. These pathways primarily involve enzymatic modifications and nuclease activities that target miRNAs bound to Argonaute (AGO) proteins in the RNA-induced silencing complex (RISC). Degradation is often triggered by interactions with target mRNAs or intrinsic sequence features, balancing miRNA abundance in response to cellular needs.[65] One prominent mechanism is target-directed miRNA degradation (TDMD), where extensive base-pairing between the miRNA and a target mRNA induces rapid decay of the miRNA. In this process, perfect or near-perfect complementarity allows the target mRNA to displace the miRNA's 3' end from the AGO2 PAZ domain, exposing it to nucleases or leading to ubiquitination and proteasomal degradation of the AGO-miRNA complex. For instance, in mammalian cells, highly complementary targets can induce conformational changes in the AGO2-miRNA complex, displacing the miRNA's 3' end and leading to its rapid decay through nuclease activity and ubiquitination of AGO2. Recent studies indicate that translation of the target RNA suppresses TDMD when triggers are located in the coding sequence compared to the 3' UTR, due to ribosome occupancy shielding the miRNA interaction sites.[66] This pathway is evolutionarily conserved and plays a key role in fine-tuning miRNA levels during development and stress responses.[67][68][69] Another critical pathway involves non-templated 3' addition of uridines (uridylation), which marks miRNAs for degradation. Terminal uridylyltransferases (TUTases) such as TUT4 (ZCCHC11) and TUT7 (ZCCHC6) catalyze the addition of uridines to the 3' end of mature miRNAs, particularly when they are dissociated from AGO or in response to suboptimal target interactions. Oligo-uridylation (typically 3-5 uridines) recruits the 3'-5' exonuclease DIS3L2, which trims the miRNA tail and leads to its complete degradation. This mechanism is selective; for example, TUT4/7 preferentially uridylate specific miRNAs like let-7 family members in human cells, accelerating their turnover during differentiation.[70][71][72] Deadenylation followed by 5'-3' exonucleolytic decay also contributes to miRNA turnover, particularly for miRNAs with unstable 3' ends. RNA-binding proteins like CUGBP1 promote shortening of the miRNA's 3' poly(A)-like tail, exposing the 5' end after decapping or AGO unloading. The 5'-3' exonuclease XRN2 then progressively degrades the miRNA from the 5' end. This pathway has been observed in human cell lines, where miR-16 family members undergo rapid deadenylation-dependent decay, with XRN2 knockdown stabilizing these miRNAs. While more commonly associated with mRNA decay, this mechanism applies to a subset of miRNAs exhibiting inherent instability.[73][74] Conversely, certain post-transcriptional modifications enhance miRNA stability. Monouridylation, the addition of a single uridine at the 3' end by TUT4/7, protects many miRNAs from degradation by reinforcing AGO binding and preventing further tailing or nuclease access. For example, mono-uridylated forms of miR-26 and miR-101 show increased resistance to exonucleases compared to unmodified versions. This modification contrasts with oligo-uridylation and helps maintain steady-state levels of housekeeping miRNAs.[70][71] Overall, mature miRNAs typically have half-lives of 24-48 hours in mammalian cells, though this varies by context, sequence, and cellular state—from as short as a few hours for stress-responsive miRNAs to over a week for stable ones like miR-122. Factors such as target availability and enzymatic modifications dynamically influence this turnover, ensuring adaptive regulation of gene expression.[75][65]

Regulatory Feedback Loops

MicroRNAs (miRNAs) participate in regulatory feedback loops that integrate them into gene regulatory networks, enabling fine-tuned control of target gene expression. These loops often involve miRNAs interacting with transcription factors (TFs) that regulate miRNA expression, creating circuits that enhance stability and precision in cellular responses. Such mechanisms are prevalent across eukaryotes and contribute to robust gene regulation by buffering noise and adapting to perturbations.[76] Incoherent feed-forward loops (FFLs) represent a key motif where a master TF activates both a miRNA and a target gene, while the miRNA represses the target, resulting in opposing regulatory effects. This structure allows the miRNA to fine-tune target protein levels by coupling mRNA and miRNA fluctuations, effectively reducing noise in protein expression. For instance, simulations demonstrate that miRNA-mediated incoherent FFLs lower the coefficient of variation in target proteins to approximately 0.1, outperforming simple TF-gene cascades (0.147) or unregulated circuits (0.25). An example occurs in Drosophila, where miR-8 targets atrophin under regulation by upstream TFs, maintaining optimal expression levels during development.[76][77] Negative feedback loops arise when miRNAs repress TFs that promote their own transcription, forming autoregulatory circuits that stabilize expression. A prominent case is miR-7, which targets repressors like E(spl) and yan to indirectly enhance its activator, Ato, in Drosophila sensory organ development. This double-negative loop buffers against environmental fluctuations, such as temperature shifts from 18°C to 31°C, preserving uniform cell fates and Ato/Yan protein levels. Loss of miR-7 disrupts this robustness, leading to variable sensory organ precursor determination only under perturbation, underscoring the loop's role in canalization during neural development.[78][79] miRNA sponges, including competing endogenous RNAs (ceRNAs) such as circular RNAs (circRNAs), modulate feedback by titrating miRNAs away from their targets, thereby derepressing gene expression. CircRNAs, formed by back-splicing, harbor multiple miRNA binding sites and act as efficient sponges due to their stability and abundance. For example, circRNAs like ciRS-7 sequester miR-7, preventing repression of its targets and altering network dynamics. This ceRNA mechanism expands regulatory circuits, allowing indirect control where sponges compete for miRNA binding, influencing TF-miRNA interactions in broader loops. A specific example of feedback in stem cell differentiation involves miR-145, which forms a double-negative loop with pluripotency factors OCT4, SOX2, and KLF4 in human embryonic stem cells (hESCs). miR-145 directly represses these TFs by binding their 3′ UTRs, reducing self-renewal markers like SSEA4, while OCT4 represses miR-145 transcription in undifferentiated cells. Upon differentiation cues, declining OCT4 levels derepress miR-145, amplifying repression of pluripotency genes and promoting lineage commitment toward mesoderm and ectoderm. This loop ensures timely exit from pluripotency, with miR-145 overexpression accelerating differentiation within 6 days.[78] Dynamic modeling of these loops reveals their capacity to ensure robust timing in developmental processes. Ordinary differential equation-based simulations of miRNA-TF feedback loops demonstrate bistability and noise resistance, where moderate repression strengths maintain stable expression trajectories despite fluctuations. In neuronal differentiation, such models show miR-9/HES1 loops adjusting oscillation timing for precise progression, while incoherent FFLs enable fold-change detection to decouple responses from absolute input levels. These insights highlight how feedback circuits provide developmental fidelity by integrating miRNA stability to prolong loop effects, though excessive degradation can shorten response durations.[76]

Cellular and Physiological Functions

Gene Expression Regulation

MicroRNAs (miRNAs) primarily regulate gene expression at the post-transcriptional level by binding to target messenger RNAs (mRNAs), leading to their degradation or translational repression, which fine-tunes protein output without altering transcription rates. This mechanism allows miRNAs to act as rheostats, modulating the expression of multiple genes simultaneously to maintain cellular homeostasis and respond to environmental cues. Through integration into the RNA-induced silencing complex (RISC), miRNAs recognize specific sequences, typically in the 3' untranslated region (3' UTR) of target mRNAs, enabling precise control over a broad regulatory network. A key function of miRNAs is buffering stochastic noise in gene expression, where they dampen fluctuations in protein levels arising from transcriptional variability, thereby enhancing phenotypic robustness. For instance, miRNAs accelerate mRNA turnover for lowly expressed genes, compensating for noise by stabilizing output through negative feedback loops that reduce cell-to-cell variability. This noise-buffering capacity is particularly evident in miRNA-mediated incoherent feedforward loops, which optimize gene expression profiles to minimize variability without substantially altering mean levels. Seminal studies have shown that miRNAs can reduce noise in target gene expression, promoting consistent cellular responses across populations.[80][81][82] miRNAs also enable thresholding effects, generating switch-like responses in signaling pathways by creating concentration-dependent repression thresholds for target proteins. In this model, miRNAs maintain low basal levels of target proteins until a signaling stimulus exceeds a critical threshold, at which point derepression occurs rapidly, amplifying the response. This is achieved through cooperative binding or feedback amplification, where miRNAs prevent premature activation of downstream effectors, ensuring digital-like outputs in dose-sensitive pathways such as Notch signaling. Experimental evidence demonstrates that such thresholding can sharpen gene expression transitions, with miRNA depletion leading to graded rather than binary responses.[83][84] Individual miRNAs often exert widespread effects by targeting numerous mRNAs, allowing one miRNA to coordinately regulate diverse cellular processes. For example, members of the let-7 family can target hundreds of transcripts, repressing proliferation and differentiation pathways en masse. This broad targeting facilitates rapid adjustments in gene networks, with a single miRNA modulating protein levels from multiple genes to achieve systemic effects.[85] Combinatorial control further enhances specificity, where multiple miRNAs converge on the same mRNA to amplify repression or fine-tune its extent based on cellular context. This cooperative action increases the precision of regulation, as the arrangement and number of binding sites on a target mRNA determine the degree of silencing, often requiring synergistic inputs for robust effects. Studies indicate that mRNAs with sites for multiple miRNAs exhibit greater repression compared to those with single sites, enabling layered control that distinguishes subtle differences in gene expression requirements.[86][87][88] Overall, miRNAs collectively repress approximately 60% of human protein-coding genes, primarily through indirect effects on translation and mRNA stability, underscoring their role as master regulators of the transcriptome. This pervasive influence arises from the evolutionary conservation of miRNA-target interactions, with most human genes harboring predicted binding sites that contribute to subtle, cumulative repression. High-throughput proteomic analyses confirm that miRNA-mediated control affects protein abundance across the majority of the genome, establishing essential context for quantitative gene network dynamics.[89]

Roles in Development and Homeostasis

MicroRNAs play essential roles in orchestrating embryonic development by facilitating the transition from maternal to zygotic gene expression. In zebrafish, miR-430 is a key regulator during embryogenesis, where it promotes the deadenylation and subsequent degradation of hundreds of maternal mRNAs, enabling the clearance of these transcripts to allow proper zygotic genome activation and patterning of the early embryo.[90] This process ensures timely cellular differentiation and prevents developmental defects, highlighting miRNAs as critical timers in early development. In mammalian systems, miRNAs contribute to maintaining stem cell pluripotency, which is vital for developmental potential and tissue regeneration. For instance, miR-291-3p, part of the embryonic stem cell-specific miR-290-295 cluster, supports the self-renewal and pluripotency of mouse embryonic stem cells by repressing differentiation-promoting factors and enhancing reprogramming efficiency when introduced into somatic cells.[91] This regulation helps sustain the undifferentiated state, buffering gene expression noise to preserve developmental flexibility.[92] Beyond development, miRNAs are integral to tissue homeostasis, maintaining metabolic balance and physiological functions in adult organisms. In the liver, miR-122, which constitutes about 70% of total hepatic miRNAs, fine-tunes lipid metabolism by targeting genes involved in cholesterol synthesis and fatty acid oxidation, thereby preventing dyslipidemia and supporting overall hepatic function.[93] Similarly, in the immune system, miR-146a acts as a negative feedback regulator of innate immune responses, inhibiting NF-κB signaling through targeting of TRAF6 and IRAK1 to resolve inflammation and prevent excessive immune activation, thus preserving immune homeostasis.[94] During aging, a global decline in miRNA expression levels across tissues contributes to the loss of regulatory control, promoting cellular senescence and organismal deterioration. The miR-34 family exemplifies this, as its members are upregulated in senescent cells to enforce cell-cycle arrest by targeting pro-proliferative genes like SIRT1 and CDK4, linking miRNA dysregulation to age-related functional decline.[92]

Evolution

Origins and Conservation

MicroRNAs (miRNAs) trace their origins to early eukaryotic evolution, with the core RNA interference (RNAi) machinery, including Argonaute and Dicer proteins, assembling in the last eukaryotic common ancestor from components derived from archaea, bacteria, and bacteriophages.[95] Proto-miRNAs likely emerged from inverted repeats or transposable elements, enabling the processing of small regulatory RNAs in primitive eukaryotic lineages.[95] The earliest characterized miRNAs, lin-4 and let-7, were identified in the nematode Caenorhabditis elegans as regulators of developmental timing, with let-7 demonstrating deep conservation across bilaterians from nematodes to mammals due to its integration into essential gene regulatory networks.[96][97] This conservation underscores the ancient role of miRNAs in modulating temporal control during development, as let-7 silences target mRNAs post-transcriptionally in a manner preserved over hundreds of millions of years.[97] The miRNA repertoire expanded dramatically in vertebrates through gene duplications, coinciding with the evolution of morphological complexity.[98] At the base of Vertebrata, 41 miRNA families arose, detectable in lampreys but absent in invertebrate chordates like amphioxus, marking a burst of innovation that contributed to the diversification of regulatory networks.[98] In humans, this expansion resulted in many vertebrate-specific miRNAs, generated via tandem and segmental duplications during whole-genome duplication events in early vertebrate history.[99] Conservation metrics highlight the stability of these ancient and expanded families: seed sequences (nucleotides 2–8 of the mature miRNA) show greater than 90% identity across bilaterians, with perfect conservation in core families like let-7, ensuring functional specificity in target recognition.[97][100] De novo evolution provides a mechanism for miRNA innovation beyond duplication, with new genes arising from randomized hairpin structures or transposable elements (TEs).[101] In humans, about 12% of miRNAs (roughly 55 out of 452 annotated at the time) originate from TEs, particularly miniature inverted-repeat transposable elements (MITEs), which supply palindromic sequences that fold into processable hairpins.[102] For instance, the mir-548 family derives from MADE1 TEs and targets thousands of genes, illustrating how TE mobilization can rapidly introduce novel regulators.[102] Phylogenetic analyses, often leveraging databases like miRBase, reconstruct miRNA family divergence by aligning precursor sequences and mature miRNAs across taxa, revealing branching patterns tied to major eukaryotic lineages.[99] These trees demonstrate that ancient families like let-7 diverged early in bilaterian evolution, while vertebrate expansions show clustered duplications, with minimal secondary losses once families are established.[97][103] Such analyses confirm miRNAs as reliable phylogenetic markers, with family presence/absence patterns reflecting deep divergences in metazoan history.[103]

Species-Specific Adaptations

In animals, microRNAs predominantly mediate gene silencing through translational repression and mRNA destabilization rather than direct cleavage, allowing for fine-tuned regulation of complex developmental and physiological processes.[104] This mechanism contrasts with more direct slicing in other organisms and enables animals to achieve nuanced control over protein synthesis without fully eliminating target transcripts. In mammals, miRNA gene clusters have undergone significant expansion, particularly through tandem duplications on the X chromosome and in vertebrate-specific lineages, contributing to increased regulatory complexity in tissues like the brain and contributing to evolutionary innovations such as corticospinal neuron development.[105][106] Recently evolved human-specific miRNAs are enriched for neuronal functions, potentially contributing to cognitive evolution.[107] In plants, microRNAs often employ a cleavage mode of action, where perfect complementarity to target mRNAs leads to endonucleolytic slicing, facilitating precise control over developmental timing. A prominent example is miR-156, which regulates the transition from juvenile to adult phases by targeting SQUAMOSA PROMOTER BINDING-LIKE (SPL) transcription factors, thereby delaying flowering and ensuring reproductive success under varying environmental cues.[108] This adaptation underscores miR-156's role in integrating age-dependent signals with flowering time pathways across diverse plant species.[109] Fungi possess fewer microRNA-like small RNAs (milRNAs) compared to animals and plants, with their biogenesis and functions adapted for niche-specific roles, particularly in pathogenesis. In the corn smut fungus Ustilago maydis, mRNAs are secreted via extracellular vesicles and may modulate host interactions during infection.[110] Viral microRNAs represent a striking adaptation, where viruses hijack host machinery to produce miRNAs that mimic cellular ones, ensuring persistence and evasion of immunity. For instance, in Kaposi's sarcoma-associated herpesvirus (KSHV), miR-K12-11 targets host factors like IKKε and components of the TGF-β pathway, thereby maintaining viral latency and suppressing lytic reactivation in infected cells.[111][112] Among invertebrates, microRNAs have evolved to fine-tune innate immune responses, with specific miRNAs acting as negative regulators to prevent excessive inflammation. In Drosophila melanogaster, miR-100 inhibits the IMD pathway by targeting the TAK1-binding protein (Tab2), thereby readjusting immune activation via NF-κB/Relish to maintain homeostasis during bacterial challenges.[113] These species-specific adaptations build upon the conserved core biogenesis of microRNAs across eukaryotes, allowing divergent functions tailored to ecological and physiological demands.[114]

Experimental Methods

Detection Techniques

Detection of microRNAs (miRNAs) is essential for understanding their expression patterns, functional roles, and dysregulation in biological processes and diseases. Traditional and modern techniques have evolved to address the challenges posed by miRNAs' small size (typically 19-25 nucleotides), low abundance, and sequence similarity to precursors and other small RNAs. These methods enable qualitative identification, quantitative measurement, and high-throughput profiling, with each offering distinct advantages in sensitivity, specificity, and applicability to different sample types. Northern blotting served as the initial gold standard for miRNA detection following the discovery of the first miRNA, lin-4, in Caenorhabditis elegans. This technique involves electrophoresis of total RNA on a denaturing polyacrylamide gel, transfer to a membrane, and hybridization with radiolabeled or biotinylated oligonucleotide probes complementary to the target miRNA, allowing visualization of mature miRNA size (around 22 nt) and abundance relative to precursors. It provides direct confirmation of miRNA maturity and length but is labor-intensive, requires relatively large RNA amounts (micrograms), and has lower sensitivity for low-abundance miRNAs compared to newer methods. Improvements using locked nucleic acid (LNA)-modified probes have enhanced hybridization specificity and signal intensity, reducing non-specific binding and enabling detection from smaller samples. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) has become a widely adopted method for precise miRNA quantification due to its high sensitivity and dynamic range. The stem-loop RT primer approach, which uses a miRNA-specific stem-loop structure to extend the short miRNA during reverse transcription, followed by TaqMan probe-based PCR, ensures specificity for mature miRNAs by distinguishing them from precursors and genomic DNA. This method detects as few as 10-100 miRNA copies per reaction and is suitable for clinical samples like plasma or tissue biopsies, with normalization to stable small RNAs such as U6 snRNA. Variations include poly(A) tailing or ligation-based priming, but the stem-loop design minimizes primer-dimer artifacts and supports multiplexing for up to 48 miRNAs. Next-generation sequencing (NGS), particularly small RNA sequencing (small RNA-seq), revolutionized miRNA discovery and profiling by enabling unbiased, genome-wide detection without prior knowledge of sequences. Libraries are prepared by ligating adapters to small RNAs (18-30 nt), size-selecting for miRNA-enriched fractions, and sequencing on platforms like Illumina, yielding millions of reads per sample. This approach identifies novel miRNAs, quantifies isomiRs (miRNA variants), and reveals expression dynamics across conditions, with depths of 1-5 million reads sufficient for most analyses. The miRDeep2 pipeline processes these data by mapping reads to a reference genome, predicting miRNA precursors via thermodynamic folding, and scoring candidates based on Dicer cleavage signatures and star strand reads, achieving over 98% accuracy for known miRNAs and identifying hundreds of novel ones in diverse species. Challenges include adapter ligation biases and RNA modifications affecting efficiency, addressed by randomized adapters in recent protocols. Microarrays provide a high-throughput alternative for known miRNA profiling, using immobilized probes on glass slides or beads to hybridize labeled small RNA samples. Early platforms employed DNA oligonucleotides, but incorporation of LNA-modified probes significantly improved specificity and sensitivity by increasing melting temperatures (up to 10°C higher than DNA), allowing shorter probes (8-12 nt) for better discrimination of single-nucleotide differences and reducing cross-hybridization with precursors. These arrays interrogate thousands of miRNAs simultaneously, with detection limits around 1-10 fmol, and are cost-effective for targeted studies in human, mouse, or plant samples. Signal intensities are quantified via fluorescence scanning, often normalized to spike-in controls, though they are less effective for novel miRNA discovery compared to sequencing. Recent advances in single-cell miRNA profiling adapt single-cell RNA sequencing (scRNA-seq) protocols to capture small RNAs, addressing heterogeneity in miRNA expression within tissues or tumors. Techniques like sc-miRNA-seq or modifications to 10x Genomics Chromium involve barcoding individual cells, depleting rRNA/tRNA, and enriching for miRNAs via size selection or hybridization capture before NGS. These approaches integrate miRNA data with mRNA profiles to infer regulatory networks, though challenges persist in low miRNA yields (hundreds of molecules per cell) and computational deconvolution of isomiRs. Such adaptations, building on 2018-2020 foundations, now support studies with improved throughput up to 10,000 cells.

Manipulation and Target Prediction

Manipulation of microRNAs (miRNAs) is essential for functional studies, enabling researchers to assess their roles in gene regulation through knockdown or overexpression approaches. AntagomiRs, chemically engineered single-stranded oligonucleotides complementary to mature miRNAs, were introduced as efficient silencers of endogenous miRNAs in vivo. These molecules, typically 21-23 nucleotides long and modified with cholesterol conjugates at the 3' end for enhanced delivery and stability, bind to target miRNAs via base-pairing, leading to their degradation or inhibition without altering genomic sequences. A seminal study demonstrated that antagomiRs specifically silenced miR-16 in mice, reducing its levels by over 90% in liver and other tissues, with effects lasting up to 23 days post-injection. Locked nucleic acid (LNA)-modified antagomiRs further improve potency and specificity; these incorporate LNA bases that increase binding affinity (Tm shift of +3-9°C per modification) and nuclease resistance, allowing effective knockdown at lower doses, such as 1-5 mg/kg in rodents. For instance, LNA-antimiR-122 achieved >95% inhibition of miR-122 in the liver, highlighting their utility in tissue-specific studies. For miRNA overexpression, synthetic miRNA mimics—double-stranded RNA oligonucleotides designed to emulate the mature miRNA duplex—are widely employed via transient transfection. These mimics, often 21-23 base pairs long with 2-nucleotide 3' overhangs, integrate into the RNA-induced silencing complex (RISC) to mimic endogenous miRNA activity, bypassing biogenesis pathways. Transfection efficiency in cell lines like HEK293 reaches 70-90% using lipid-based reagents such as Lipofectamine, resulting in 10-100-fold increases in functional miRNA levels. However, caution is advised, as high concentrations (>100 nM) can trigger off-target effects, including interferon responses, potentially distorting physiological outcomes. Mimics have been pivotal in elucidating miRNA functions, such as miR-21's role in apoptosis suppression when overexpressed in cancer cells. Genome editing technologies like CRISPR-Cas9 provide precise, stable manipulation of miRNA loci. Cas9 nucleases, guided by single-guide RNAs (sgRNAs) targeting miRNA precursors or flanking regions, induce double-strand breaks that, upon non-homologous end joining (NHEJ), create insertions/deletions (indels) disrupting miRNA maturation. This approach achieved >90% knockout efficiency for miR-17~92 cluster in human cells, revealing its oncogenic roles. Dual sgRNAs enhance precision by excising entire miRNA clusters, reducing off-target effects to <1% in validated sites. In plants, CRISPR-Cas9 edited miR-396, confirming its regulation of growth genes with 80-100% mutation rates in regenerated lines. CRISPR-based interference using catalytically dead Cas13 (dCas13) offers RNA-level modulation without genomic alterations. dCas13, an RNA-guided RNA-binding protein, targets mature miRNAs or precursors via direct complementarity, sterically blocking RISC loading or Argonaute association. Studies have shown dCas13 can repress miRNA activity in mammalian cells by shielding mRNA targets, with applications in disease models. This method's reversibility and low immunogenicity make it suitable for dynamic studies, though guide RNA design requires >90% complementarity for efficacy. Target prediction algorithms computationally identify potential miRNA-mRNA interactions, guiding experimental validation. TargetScan, developed in 2003, prioritizes conserved 6-8mer seed matches (positions 2-8 of the miRNA) in 3' UTRs, incorporating site accessibility and evolutionary conservation across vertebrates to score targets. It predicts targets for over 2,000 human miRNAs, estimating that miRNAs regulate ~60% of genes, with validation rates of 50-70% in reporter assays. miRanda, introduced concurrently, employs thermodynamic modeling via dynamic programming to evaluate full miRNA-mRNA duplex stability (ΔG < -20 kcal/mol threshold), emphasizing 5' seed pairing and 3' UTR conservation, yielding ~2,000 high-confidence human targets enriched for developmental pathways. Databases like miRTarBase aggregate experimentally validated interactions, curating data from literature and high-throughput screens. The 2025 release documents over 3,817,550 miRNA-target interactions (MTIs) across 288 species, derived from 13,690 publications, including 497 CLIP-seq datasets that map Argonaute binding sites with >80% specificity. It classifies evidence by strength (strong: reporter assays; weak: microarray), facilitating prioritization; for example, miR-21 has >1,000 validated targets linked to cancer. Validation of predicted targets commonly employs luciferase reporter assays, which quantify miRNA-mediated repression. The method fuses candidate 3' UTR segments (wild-type or mutated seed sites) downstream of a firefly luciferase gene in a plasmid, co-transfected with miRNA mimics or inhibitors into cells (e.g., HEK293). Renilla luciferase serves as a normalization control; functional targeting reduces firefly activity by 40-80% via mRNA destabilization or translation inhibition. Seminal validations, such as lin-41 for let-7, confirmed direct binding with >50% repression, establishing this as the gold standard for direct interactions.

Roles Across Organisms

In Animals and Humans

In animals, microRNAs (miRNAs) play pivotal roles in regulating gene expression post-transcriptionally, primarily through imperfect base-pairing with target mRNAs in the 3' untranslated region, leading to translational repression or mRNA destabilization. This mechanism contrasts with plant miRNAs, which typically exhibit near-perfect complementarity and induce target mRNA cleavage. In mammalian systems, including humans, miRNAs contribute to diverse physiological processes such as tissue differentiation, homeostasis, and temporal regulation of cellular functions.[115] Approximately 2,600 miRNAs have been annotated in the human genome, with many exhibiting tissue-specific expression patterns that underpin organ identity and function.01706-7) Tissue-specific miRNAs are crucial for maintaining specialized cellular states in animals. For instance, miR-1 is highly expressed in skeletal and cardiac muscle, where it modulates muscle development and contractility by targeting genes involved in myogenesis, such as those in the Hand2 and histone deacetylase 4 pathways. Similarly, miR-122 predominates in the liver, accounting for about 70% of hepatic miRNA transcripts, and regulates lipid metabolism by repressing genes like cationic amino acid transporter 1, thereby influencing cholesterol homeostasis and hepatocyte differentiation. These examples illustrate how miRNAs enforce tissue-specific gene silencing in mammalian physiology.[116][117] miRNAs also participate in temporal regulation, such as circadian rhythms. In the suprachiasmatic nucleus, the master clock in mammals, miR-132 modulates clock gene expression by targeting regulators of chromatin remodeling and translation, thereby fine-tuning circadian periodicity and entrainment to light cues; its overexpression shortens the circadian period, while knockdown lengthens it. In reproductive physiology, miR-10b is abundantly expressed in ovarian granulosa cells and follicular fluid, where it suppresses proliferation by targeting brain-derived neurotrophic factor, indirectly supporting oocyte maturation and follicular development in mammals like goats and cows.00374-1)[118] In humans, miRNAs are integral to immune homeostasis. miR-155, for example, is upregulated in activated immune cells and promotes inflammatory responses by enhancing T-cell differentiation and cytokine production through repression of ship1 and socs1, thereby shaping adaptive immunity without invoking pathological states. Evolutionary adaptations have further diversified these roles, with animal miRNAs evolving to buffer gene expression noise across tissues.00351-1)

In Plants

MicroRNAs (miRNAs) play crucial roles in plant biology, regulating gene expression to influence growth, stress adaptation, and reproduction. In plants, miRNAs often exhibit unique biogenesis features, such as reliance on the DICER-LIKE1 (DCL1) processor without the need for animal-like Drosha homologs, enabling precise temporal and spatial control. Unlike in animals, plant miRNAs typically mediate transcript cleavage rather than translational repression, amplifying their regulatory impact on developmental and environmental responses.00128-7) A prominent function of miRNAs in plant development involves timing the transition from vegetative to reproductive phases. miR-156 acts as a master regulator of juvenile-to-adult vegetative phase change by targeting SPL (SQUAMOSA PROMOTER BINDING PROTEIN-LIKE) transcription factors, whose increasing levels as miR-156 declines promote adult traits like larger leaves and inflorescence competence. This gradual decline in miR-156 expression ensures proper timing of flowering, as observed in Arabidopsis where miR-156 overexpression delays the vegetative-to-floral shift by several weeks. Complementing this, miR-159 fine-tunes the process by repressing MYB transcription factors such as MYB33 and MYB65, which otherwise promote flowering; reduced miR-159 activity accelerates the transition, highlighting its role in integrating age-dependent signals with floral pathways. These miRNAs collectively orchestrate developmental progression, preventing premature reproduction in response to environmental cues.00082-3)00608-1)[119] In nutrient homeostasis, miR-399 exemplifies miRNA-mediated adaptation to phosphate (Pi) limitation, a critical stress for plant growth. Under Pi starvation, miR-399 expression surges in shoots, leading to its transport via the phloem to roots where it cleaves PHO2 mRNA, an E2 ubiquitin-conjugase that normally degrades Pi transporters like PHT1. This derepression enhances Pi uptake and translocation, as demonstrated in Arabidopsis mutants where miR-399 overexpression restores growth under low-Pi conditions by elevating systemic Pi levels. Such regulation forms a feedback loop with the phosphate starvation response (PHR) pathway, ensuring efficient resource allocation during deficiency.00128-7)[120]00215-0) For biotic stress responses, miR-164 modulates pathogen resistance by targeting NAC domain transcription factors, which control defense-related cell death. In Arabidopsis, miR-164 represses NAC4, preventing excessive hypersensitive response (HR) and programmed cell death that could compromise tissue integrity during infection; nac4 mutants exhibit heightened susceptibility to bacterial pathogens like Pseudomonas syringae due to reduced HR and compromised defense response.[121] Similarly, in wheat, tae-miR164 targets a NAM-subfamily NAC to fine-tune resistance against stripe rust fungus, where elevated miR-164 levels suppress NAC accumulation and limit fungal spread. This negative regulation balances immunity and growth, allowing plants to mount targeted defenses without broad developmental disruption. miRNAs also contribute to abiotic stress tolerance, particularly through miR-398's role in mitigating oxidative damage. miR-398 targets transcripts encoding copper/zinc superoxide dismutases (CSD1, CSD2) and cytochrome c oxidase assembly protein (CCS1), enzymes that detoxify reactive oxygen species (ROS) under stresses like drought or high light. During oxidative stress, miR-398 levels decrease, stabilizing these targets to boost ROS scavenging and prevent cellular damage, as seen in Arabidopsis where miR-398 overexpression impairs tolerance to methyl viologen-induced oxidative stress. This dynamic regulation integrates retrograde chloroplast signals, enhancing plant resilience to environmental fluctuations.00026-X)[122]31030-X) Beyond local action, miRNAs serve as mobile signals in plants, traveling through the phloem to coordinate intercellular and systemic responses. For instance, miR-399 moves from shoots to roots to regulate Pi homeostasis remotely, while miR-2111 translocates from shoots to influence root branching and nitrogen uptake in response to nutrient availability. This mobility, facilitated by plasmodesmata and sieve elements, enables long-distance communication, as evidenced by grafting experiments where miRNA movement restores stress responses in recipient tissues. Such signaling underscores miRNAs' versatility in integrating whole-plant physiology during development and stress.[123][124]00215-0)

In Viruses

Viruses encode microRNAs (miRNAs) that are processed and function similarly to host miRNAs, hijacking the host's RNA interference machinery to regulate gene expression during infection. To date, miRBase annotates approximately 353 mature viral miRNAs derived from 20 different viruses (as of miRBase v22.1), with the majority—over 299—originating from herpesviruses, reflecting their complex life cycles involving latency and reactivation.[125][126] These viral miRNAs (v-miRNAs) are transcribed as primary transcripts (pri-miRNAs) from viral genomes and rely entirely on the host's nuclear Drosha and cytoplasmic Dicer enzymes for maturation into functional ~22-nucleotide duplexes, which are then loaded into Argonaute proteins within the RNA-induced silencing complex (RISC) to mediate post-transcriptional repression of target mRNAs.[127] A well-characterized example is herpes simplex virus 1 (HSV-1) miR-H2, encoded within the latency-associated transcript (LAT) region, which is abundantly expressed during latent infection in neurons and uses host machinery to fine-tune viral gene expression.[128] Viral miRNAs play critical roles in modulating host-virus interactions to favor viral persistence, particularly through immune evasion and maintenance of latency. In Epstein-Barr virus (EBV), the BART (BamHI-A rightward transcript) miRNAs, such as miR-BART7, downregulate major histocompatibility complex class I (MHC I) molecules on infected cells, thereby reducing antigen presentation to cytotoxic T cells and facilitating escape from adaptive immunity.[129] Similarly, in Kaposi's sarcoma-associated herpesvirus (KSHV), a cluster of 12 miRNAs expressed from the latency-associated region inhibits lytic replication by targeting viral immediate-early genes like RTA (replication and transcription activator) and host factors, thereby promoting the establishment and maintenance of viral latency in infected cells.[130] These mechanisms underscore how v-miRNAs selectively repress host immune pathways while sparing viral propagation. Beyond direct viral regulation, v-miRNAs engage in host-virus crosstalk by targeting cellular pathways essential for antiviral defense, including apoptosis. For instance, EBV miR-BHRF1-3 targets pro-apoptotic genes such as PUMA (p53 upregulated modulator of apoptosis), inhibiting host cell death and allowing prolonged viral persistence in B lymphocytes.[131] KSHV miRNAs similarly target apoptosis regulators like BCLAF1, enhancing infected cell survival and contributing to oncogenesis in conditions like Kaposi's sarcoma.[132] Recent studies have extended these findings to RNA viruses; in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infection generates small viral RNAs (svRNAs) that mimic miRNAs, such as CoV2-miR-O8, which are processed by host Dicer and loaded into RISC to repress host genes involved in interferon responses and apoptosis, thereby aiding viral replication in airway epithelial cells.[133][134] These svRNAs highlight an emerging paradigm where even non-enveloped RNA viruses exploit miRNA-like mechanisms for pathogenesis.

Involvement in Diseases

Genetic and Inherited Disorders

MicroRNAs (miRNAs) play essential roles in gene regulation, and mutations in miRNA genes or their processing factors can disrupt these functions, leading to monogenic disorders. These genetic alterations typically affect miRNA biogenesis, maturation, or target binding, resulting in developmental or physiological abnormalities. At least 13 miRNA-related Mendelian disorders have been documented as of 2024, underscoring the non-redundant contributions of specific miRNAs and processing components to human health.[135] A key example involves deletions encompassing the DGCR8 gene in DiGeorge syndrome (22q11.2 deletion syndrome), a contiguous gene disorder that impairs miRNA processing. DGCR8, a core component of the microprocessor complex, facilitates pri-miRNA cleavage by Drosha; its haploinsufficiency reduces global miRNA levels, particularly in immune cells, contributing to thymic hypoplasia, T-cell lymphopenia, and increased susceptibility to infections. Studies in patient-derived cells and mouse models confirm that DGCR8 deficiency disrupts immune development by dysregulating miRNA-mediated control of proliferation and differentiation in thymocytes.[136][137][138] Mutations in the MIR96 gene exemplify direct effects of miRNA sequence variants in monogenic disease. These cause autosomal dominant nonsyndromic hearing loss (DFNA50), with postlingual onset in the second decade of life and progressive high-frequency sensorineural impairment. Point mutations, such as c.13G>A (p.Ala4Thr) in the seed region, alter miR-96's binding to target mRNAs, including those involved in inner ear hair cell maintenance like Gfi1 and Ptprz1, leading to stereocilia degeneration and auditory dysfunction. Functional assays in zebrafish and mouse models demonstrate that these variants confer gain-of-toxic-function or loss-of-repression effects on hair cell genes.[139] Pri-miRNA polymorphisms can also contribute to susceptibility to complex autoimmune diseases. For instance, the rs2910164 C>G variant in pri-miR-146a reduces mature miR-146a levels, impairing its negative regulation of NF-κB signaling and Toll-like receptor pathways, thereby increasing susceptibility to autoimmune conditions like systemic lupus erythematosus and rheumatoid arthritis. Meta-analyses of case-control studies link the G allele to elevated autoimmunity risk, with odds ratios indicating modest but significant effects in diverse populations.[140][141] Inheritance patterns in miRNA-related disorders reflect the underlying genetic mechanisms. Autosomal dominant transmission predominates in cases like DFNA50 due to MIR96 mutations, where a single altered allele suffices to disrupt miRNA function through dominant-negative or haploinsufficient effects. In contrast, some biogenesis factor disorders, such as those involving DROSHA variants, exhibit autosomal recessive patterns requiring biallelic loss for full penetrance, though incomplete dominance can occur. Mutations in biogenesis genes like DROSHA and DICER1 briefly reference broader impacts on miRNA processing in syndromes including Wilms tumor predisposition. Overall, these patterns highlight the dosage sensitivity of miRNA pathways in Mendelian inheritance.[135][142]

Oncogenic Roles in Cancer

MicroRNAs (miRNAs) play pivotal roles in cancer by dysregulating gene expression, either promoting tumorigenesis as oncomiRs or inhibiting it as tumor suppressors.[143] In oncogenic contexts, certain miRNAs are overexpressed to suppress tumor-suppressive pathways, facilitating cell proliferation, survival, and invasion. Conversely, downregulation of tumor-suppressive miRNAs removes brakes on proto-oncogenic signaling, contributing to cancer initiation and progression. These dysregulations often arise from genetic alterations, epigenetic modifications, or environmental cues, highlighting miRNAs' integration into core cancer hallmarks.[144] A prototypical oncomiR is miR-21, which is overexpressed in numerous solid tumors, including breast, lung, colorectal, and prostate cancers, where it enhances proliferation and inhibits apoptosis by targeting the tumor suppressor PTEN.[145] By binding to the 3' untranslated region of PTEN mRNA, miR-21 reduces PTEN protein levels, leading to hyperactivation of the PI3K/AKT pathway and increased cellular survival.[144] This overexpression correlates with advanced disease stages and poor prognosis across multiple cancer types, underscoring miR-21's broad oncogenic impact.[145] In contrast, the miR-34 family acts as a key tumor suppressor, directly transactivated by the p53 transcription factor in response to DNA damage or oncogenic stress.[146] Members such as miR-34a, miR-34b, and miR-34c are frequently downregulated in many human cancers due to p53 mutations or epigenetic silencing, resulting in unchecked cell cycle progression and reduced senescence.[143] Loss of miR-34 function promotes epithelial-mesenchymal transition (EMT) and metastasis by derepressing targets like SNAIL, MET, and CDK4/6, thereby accelerating tumor aggressiveness.[143] miR-10b exemplifies miRNAs driving metastasis, particularly in breast cancer, where its upregulation by the TWIST1 transcription factor inhibits HOXD10, a repressor of prometastatic genes.[147] This suppression enhances cell migration and invasion by upregulating pro-invasive factors like RhoC and matrix metalloproteinases, facilitating distant tumor spread in preclinical models.[147] Elevated miR-10b levels in primary tumors predict higher metastatic risk and poorer outcomes.[147] Circulating miRNAs offer non-invasive diagnostic potential in cancer; for instance, plasma levels of miR-141 are significantly elevated in prostate cancer patients compared to healthy controls, serving as a biomarker for early detection.[148] This elevation reflects tumor-derived exosomal release and correlates with disease progression, providing higher specificity than prostate-specific antigen alone in some cohorts.[149] Recent studies also implicate the miR-23 cluster (miR-23a/27a/24-2) in therapy resistance, where its overexpression in gastric and other cancers fosters immune evasion and PD-1/PD-L1 blockade failure by modulating apoptotic and inflammatory pathways.[150] This cluster's role highlights emerging targets for overcoming resistance in immunotherapy.[151]

Cardiovascular and Metabolic Diseases

MicroRNAs play critical roles in the pathogenesis of cardiovascular and metabolic diseases by regulating gene expression involved in vascular integrity, lipid metabolism, and insulin signaling. Dysregulation of specific miRNAs contributes to conditions such as aortic aneurysms, atherosclerosis, diabetes, and obesity through mechanisms that alter extracellular matrix remodeling, cholesterol handling, and cellular function.[152][153][154] In cardiovascular diseases, particularly abdominal aortic aneurysms (AAA), miR-712 in rodents and its human homolog miR-205 promote disease progression by targeting tissue inhibitor of metalloproteinase 3 (TIMP3). In mouse models infused with angiotensin II, miR-712 is upregulated, leading to suppression of TIMP3 and reversion-inducing cysteine-rich protein with Kazal motifs (RECK), which enhances matrix metalloproteinase (MMP) activity, elastin degradation, and aortic dilation characteristic of AAA.[155][152] Inhibition of miR-712 using anti-miRNA oligonucleotides prevents AAA formation by restoring TIMP3 and RECK expression, reducing MMP activation and vascular inflammation.[155] In humans, miR-205 similarly downregulates TIMP3, contributing to MMP-mediated extracellular matrix breakdown in aneurysmal tissues, as validated in endothelial cells where miR-205 repression of TIMP3 promotes inflammatory responses.[152][156] Disturbed shear stress, a key hemodynamic factor in vascular pathology, induces miR-712 expression in endothelial cells, linking biomechanical forces to aneurysm development. Low or oscillatory shear stress upregulates miR-712 derived from pre-ribosomal RNA, which in turn drives endothelial inflammation and atherosclerosis by targeting anti-inflammatory genes.[157] A 2021 study shows miR-205's role in downregulating low-density lipoprotein receptor-related protein 1 (LRP-1) in patients with familial hypercholesterolemia, exacerbating cardiovascular disease progression through impaired lipid clearance and plaque instability.[158] Another study demonstrates that upregulation of miR-205-5p alleviates atherosclerosis in apolipoprotein E-deficient mice by modulating the ERBB4/AKT pathway, highlighting its therapeutic potential in shear stress-associated vascular remodeling.[159] In atherosclerosis, miR-33 regulates cholesterol efflux by repressing ATP-binding cassette transporters ABCA1 and ABCG1 in macrophages and hepatocytes. Elevated miR-33 levels impair reverse cholesterol transport, leading to lipid accumulation in plaques and accelerated disease in low-density lipoprotein receptor-deficient mice.[153] Antagonism of miR-33 with locked nucleic acid inhibitors enhances ABCA1 expression, promotes high-density lipoprotein biogenesis, and reduces atherosclerotic lesion size by up to 40% in advanced disease models.[160][153] This miR-33-mediated control of cholesterol homeostasis underscores its contribution to plaque inflammation and instability.[160] Metabolic diseases involving miRNAs include diabetes, where miR-375 critically influences pancreatic beta-cell function and insulin secretion. In beta cells, miR-375 targets myotrophin (Mtpn) and other genes to suppress proliferation and maintain glucose-stimulated insulin release, with overexpression leading to reduced beta-cell mass and hyperglycemia in mouse models.[154][161] Genetic deletion of miR-375 impairs beta-cell function, resulting in elevated alpha-cell mass and disrupted glycemic control, while circulating miR-375 levels serve as a biomarker for beta-cell death in type 1 and type 2 diabetes.[162][154] A 2025 review confirms miR-375's dosage-dependent regulation of insulin production, positioning it as a key modulator in diabetes pathogenesis.[154] Obesity-related miRNA dysregulation is exemplified by miR-14 in Drosophila, which governs fat metabolism and energy homeostasis. In fruit flies, miR-14 mutants exhibit increased triacylglycerol and diacylglycerol levels due to impaired lipid catabolism and elevated caspase activity, leading to fat accumulation and metabolic imbalance.[163][164] miR-14 acts in insulin-producing neurosecretory cells to regulate systemic metabolism, with its loss promoting insulin overproduction and obesity-like phenotypes.[165] Human analogs, such as miR-376 family members, share conserved roles in adipocyte differentiation and lipid storage, suggesting evolutionary parallels in obesity mechanisms.[166]

Neurological and Other Disorders

MicroRNAs (miRNAs) play critical roles in neurological disorders by regulating gene expression in neuronal cells, influencing processes such as neuroprotection, addiction, and synaptic function. In ischemic stroke, miR-124 provides neuroprotection by mitigating neuronal death following ischemia. Overexpression of miR-124 in animal models reduces infarct size and improves neurological outcomes after focal cerebral ischemia, primarily by suppressing pro-apoptotic pathways and promoting neuronal survival.[167] Similarly, delivery of miR-124 via exosomes enhances neurogenesis in the post-ischemic brain, targeting factors that inhibit neural stem cell proliferation.[168] In alcoholism, miR-9 is downregulated in addiction pathways, contributing to neuroadaptations in the prefrontal cortex. Chronic alcohol exposure in mouse models leads to consistent downregulation of the pri-mir-9-1 precursor to approximately 50% of baseline levels, altering BK channel splice variant stability and ethanol sensitivity.[169] This miR-9-mediated posttranscriptional regulation facilitates tolerance and dependence by reorganizing ion channel expression in reward-related brain regions.[170] miR-134 regulates synaptic plasticity in the nervous system, particularly by controlling dendritic spine morphology and long-term potentiation. In hippocampal neurons, miR-134 limits spine volume by inhibiting translation of Limk1 mRNA in dendrites, thereby fine-tuning actin dynamics essential for synaptic strengthening.[171] Synaptic activity relieves this miR-134 repression, allowing Limk1 expression to support plasticity, a mechanism conserved across neuronal development and memory formation.[172] In kidney disease, miR-192 contributes to diabetic nephropathy pathogenesis through interactions with ZEB2. Elevated miR-192 in glomerular cells of diabetic models targets ZEB2, a transcriptional repressor, leading to derepression of extracellular matrix genes like Col1a1 and Col1a2, which promotes fibrosis.[173] Inhibition of miR-192 in diabetic mice kidneys upregulates ZEB2, reducing collagen and TGF-β expression, thereby ameliorating renal fibrosis and proteinuria.[174] miRNAs also influence hemostasis, with miR-223 regulating platelet function to maintain vascular integrity. miR-223, highly expressed in platelets, targets P2Y12 receptor mRNA, modulating ADP-induced aggregation and preventing excessive thrombosis.[175] Deficiency of miR-223 in hematopoietic cells attenuates arterial thrombosis in mice, highlighting its role in balancing hemostatic responses.[176] In obesity, miR-221 links altered metabolism to hemostatic dysregulation by enhancing platelet reactivity. Elevated platelet miR-221 levels correlate with high on-treatment platelet reactivity in obese individuals, promoting hypercoagulability through pathways that amplify aggregation.[177] This upregulation contributes to obesity-associated thrombotic risk by dysregulating genes involved in platelet activation.[178]

Clinical and Therapeutic Applications

Diagnostic Biomarkers

MicroRNAs (miRNAs) circulating in biofluids such as blood have emerged as promising non-invasive diagnostic biomarkers due to their stability and detectability in cell-free forms, including exosomes and lipoprotein complexes. These circulating miRNAs are protected from degradation by RNases, enabling their persistence in plasma and serum for hours to days, which facilitates reliable sampling and analysis. For instance, miR-208a, a cardiac-specific miRNA, is rapidly released into the bloodstream following cardiomyocyte necrosis and serves as an early indicator of acute myocardial infarction (AMI), with levels increasing up to 51-fold within 24 hours post-onset.[179][180] This stability in exosomes allows for the detection of tissue-derived signals without invasive procedures, distinguishing miRNAs from more labile biomarkers like proteins. Multi-miRNA panels enhance diagnostic accuracy by combining signatures that reflect disease-specific dysregulation, often outperforming single markers. A serum panel including miR-21 and miR-155, both upregulated in various malignancies, has shown utility in breast cancer screening, achieving improved sensitivity through their synergistic profiling via quantitative reverse transcription polymerase chain reaction (qRT-PCR).[181] These panels leverage the complementary expression patterns of miRNAs involved in oncogenic pathways, such as inflammation and proliferation, to differentiate cancerous from healthy states. qRT-PCR assays, widely adopted for their high sensitivity and specificity in miRNA quantification, enable rapid, cost-effective testing suitable for clinical settings.[182] Key advantages of miRNA biomarkers include their tissue specificity, which allows targeted detection of organ damage, and their potential for early disease identification before symptomatic onset. For example, certain miRNAs exhibit organ-enriched expression, enabling precise localization of pathology, while their altered levels can precede morphological changes detectable by imaging. Validation studies using receiver operating characteristic (ROC) curves have demonstrated robust performance, with some panels achieving over 90% specificity; one such panel for non-small cell lung cancer yielded 98% specificity and 82.7% sensitivity for miR-141 in distinguishing early-stage disease from controls.[183] These metrics underscore miRNAs' role in improving diagnostic precision across cardiovascular, oncogenic, and other disorders. Recent reviews highlight evolving applications, such as miR-23's role as a diagnostic biomarker in multiple human diseases, including cancers and inflammatory conditions, due to its dysregulation in pathogenesis and accessibility in circulation. A 2024 analysis emphasized miR-23's potential for non-invasive monitoring, building on its validated expression changes in disease cohorts.[184]

Therapeutic Strategies

Therapeutic strategies targeting microRNAs (miRNAs) primarily involve the use of synthetic mimics to restore suppressed miRNA function or inhibitors (such as antagomiRs) to block overexpressed miRNAs, aiming to modulate gene expression in disease contexts. These approaches have advanced from preclinical models to clinical testing, particularly in cancer, viral infections, and cardiovascular conditions, though challenges like stability, specificity, and immune activation persist. Delivery systems, including lipid nanoparticles and viral vectors, are crucial for effective administration, while emerging gene editing techniques offer potential for permanent modifications. miRNA mimics are double-stranded RNA oligonucleotides designed to replicate the function of endogenous miRNAs that are downregulated in disease. A prominent example is the synthetic miR-34 mimic, which targets tumor suppressor pathways by repressing oncogenes like BCL2 and MET. The liposomal formulation MRX34 entered phase I clinical trials in 2013 for advanced solid tumors, demonstrating partial responses in some patients and acceptable safety up to a maximum tolerated dose of 110 mg/m², but was discontinued in 2016 due to severe immune-related adverse events, including five patient deaths. Recent preclinical advances include redesigned miR-34a mimics with chemical modifications for enhanced stability and reduced immunogenicity, such as those conjugated to targeting ligands for prostate cancer, showing promise in 2024 studies for selective tumor delivery. Other mimics, like miR-15a/194 combinations with gemcitabine, are under investigation for pancreatic cancer in preclinical models as of 2024. miRNA inhibitors, often chemically modified antagomiRs using locked nucleic acid (LNA) technology, silence pathogenic miRNAs by sequestering them from target mRNAs. A key success is the antagomiR targeting miR-122, which stabilizes hepatitis C virus (HCV) RNA; the LNA-modified Miravirsen (SPC3649) achieved sustained viral load reductions in phase II trials (NCT01200420 and NCT01872936), with doses up to 5 mg/kg subcutaneously leading to undetectable HCV RNA in some chronic patients for up to 4 months post-treatment, though development halted after 2016 due to the rise of direct-acting antivirals. Another example is the miR-92a inhibitor MRG-110, an LNA-modified oligonucleotide that promotes angiogenesis by derepressing targets like KLF2; it advanced to phase I trials (NCT03603431) in 2018 for wound healing and revascularization in peripheral artery disease, showing enhanced vascular growth in preclinical ischemia models without significant toxicity. As of 2025, development of MRG-110 has not advanced beyond phase I. Effective delivery remains a core challenge, as naked miRNAs degrade rapidly and exhibit poor cellular uptake due to their negative charge. Lipid nanoparticles (LNPs) encapsulate miRNAs for protection and facilitate endosomal escape, as used in MRX34, but can trigger innate immune responses via Toll-like receptors. Adeno-associated virus (AAV) vectors, such as AAV9, enable sustained expression of miRNA inhibitors or mimics in tissues like muscle or liver, with preclinical efficacy demonstrated in spinal bulbar muscular atrophy models using miR-196a. Off-target effects pose significant risks, as miRNAs regulate hundreds of genes, potentially causing unintended silencing or toxicity; strategies like tissue-specific promoters and modified backbones mitigate this, though clinical translation requires further optimization. As of 2025, fewer than 20 miRNA-based therapeutics have entered clinical trials, spanning oncology, cardiology, and infectious diseases, with a focus on inhibitors due to their simpler design. No miRNA therapy has reached phase III approval, but these trials underscore growing feasibility. Gene therapy approaches using CRISPR-Cas9 target miRNA loci directly for heritable corrections in genetic diseases. Preclinical studies have edited miRNA genes like miR-96 in auditory neuropathy models, restoring hearing by precise indels at seed regions, and miR-208a in cardiomyopathy to alleviate fibrosis. While clinical applications remain early-stage, CRISPR editing of miRNA biogenesis pathways (e.g., Drosha mutations in congenital disorders) shows potential for monogenic conditions, with base editing variants reducing off-target risks in cell models.

Challenges and Advances

One major challenge in microRNA (miRNA) therapeutics is the limited stability of miRNAs in vivo, where unmodified RNA molecules are rapidly degraded by nucleases in biological fluids, hindering their therapeutic efficacy.[185] Additionally, miRNAs can trigger immune activation through recognition by innate immune sensors like Toll-like receptors, leading to inflammatory responses and potential toxicity that complicate clinical translation. Delivery specificity remains a critical barrier, as achieving targeted accumulation at disease sites without off-target effects or insufficient uptake in vivo often requires advanced vector systems to overcome biodistribution issues.[186] Recent advances have illuminated the nuclear functions of miRNAs, expanding their regulatory roles beyond cytoplasmic mRNA silencing to include transcriptional modulation and chromatin remodeling, as highlighted in 2023 reviews that underscore their implications for gene activation in cancer and immunity.[187] Exosome-based delivery systems represent a promising innovation, leveraging these natural extracellular vesicles for miRNA encapsulation due to their low immunogenicity, enhanced biocompatibility, and ability to cross biological barriers like the blood-brain barrier, with preclinical studies demonstrating improved tumor targeting and reduced adverse effects.[188][189] The miRTarBase database received significant updates in 2025, incorporating over 3,817,550 experimentally validated miRNA–target interactions from 13,690 publications, along with new modules on miRNA-drug interactions to better predict roles in resistance and refine therapeutic target selection.[190] Clinical progress in miRNA therapeutics has accelerated, with multiple candidates advancing through phase II trials for cancers and cardiovascular conditions, and experts anticipating the first regulatory approvals for miRNA mimics or inhibitors between 2025 and 2026 based on promising safety profiles in ongoing studies.[191] Looking ahead, artificial intelligence (AI) is poised to revolutionize miRNA target design by employing transformer-based models to predict binding sites with higher accuracy, integrating sequence data and structural features to minimize off-target risks.[192] Combination therapies, such as pairing miRNA inhibitors with chemotherapeutic agents like doxorubicin, are emerging as a strategy to enhance efficacy and overcome resistance, with nanogel-based co-delivery systems showing synergistic antitumor effects in preclinical models.[193]

References

User Avatar
No comments yet.